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Investigation of the Vesicular Stomatitis Virus Matrix Protein: Uncoating and
Assembly
Abstract
Vesicular Stomatitis Virus (VSV) is a simple, enveloped, nonsegmented negative-strand RNA virus and is
the prototype rhabdovirus to study viral entry, transcription, replication, and assembly. The matrix protein
(M) of VSV is a central component of the viral replication cycle. While being the smallest of the viral
proteins it is multifunctional and is involved in uncoating, cytopathic effects (CPE), and assembly of the
virus. M protein interactions involved in the uncoating and assembly of VSV have been examined in this
dissertation.
Uncoating of VSV involves dissociation of M from the ribonucleoprotein core (RNPs) of the virus. Current
models of VSV uncoating propose that following membrane fusion M protein is released from the RNP
with subsequent diffusion of M into the cytoplasm and distribution of some of the released M to the
nucleus of a host cell. The studies in Chapter 2 investigated where in the endocytic pathway uncoating
occurs, where M is located following uncoating, and the role of the cytoskeleton in distribution of input M
by using a VSV, containing fluorescent M protein (rVSV-M-Lumio-Green). I found that uncoating occurs
primarily in early endosomes and results in the majority of M remaining associated with the endosomal
membrane which eventually localizes to the perinuclear recycling endosomes. A small fraction of M,
which is presumably released into the cytosol, gets delivered to the nuclear envelope, and I found that the
typical polymerized actin or microtubules within host cells were not required for distribution of M to the
nuclear envelope.
Uncoating and assembly of the VSV genome occurs on membranes within the cytoplasm of the host cell.
Exactly how both of these processes can occur in the same environment (e.g. the cytoplasmically
exposed membrane surface) without modification of M protein by phosphorylation, cleavage, or some
other change has been an intriguing question in the field. In Chapter 3 I present results showing a pH
effect on the M-Lumio-Green protein fluorescence in vitro and during the endocytosis of virions which was
dependent on G protein. I also observed that low pH enhanced the release of M from rVSV-wt virions,
which suggested that acidification of the virus interior results in the dissociation of M contacts within the
virus enhancing the uncoating process.
An exposed protease-sensitive loop located between amino acids 120 to 129 of M has been shown to be
important for M protein self-association and has been proposed to be crucial for assembly of virions. This
knowledge comes from protease treated, purified M protein and not from mutagenesis studies. In Chapter
4 I examined mutations in the exposed loop and in particular a conserved aspartate at residue 125 of a
conserved LXD sequence. I found that virions with mutations at residue 123 or 125 of the LXD motif have
two phenotypes; 1) an assembly defect and 2) reduced viral protein synthesis starting at 4 hours post
infection. These two phenotypes have not been separated genetically and the LXD motif may represent a
motif of M involved in assembly and support of VSV protein translation.Vesicular Stomatitis Virus (VSV)
is a simple, enveloped, nonsegmented negative-strand RNA virus and is the prototype rhabdovirus to
study viral entry, transcription, replication, and assembly. The matrix protein (M) of VSV is a central
component of the viral replication cycle. While being the smallest of the viral proteins it is multifunctional
and is involved in uncoating, cytopathic effects (CPE), and assembly of the virus. M protein interactions
involved in the uncoating and assembly of VSV have been examined in this dissertation.
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Abstract
Vesicular Stomatitis Virus (VSV) is a simple, enveloped, nonsegmented negativestrand RNA virus and is the prototype rhabdovirus to study viral entry, transcription,
replication, and assembly. The matrix protein (M) of VSV is a central component of the
viral replication cycle. While being the smallest of the viral proteins it is multifunctional
and is involved in uncoating, cytopathic effects (CPE), and assembly of the virus. M
protein interactions involved in the uncoating and assembly of VSV have been examined
in this dissertation.
Uncoating of VSV involves dissociation of M from the ribonucleoprotein core
(RNPs) of the virus. Current models of VSV uncoating propose that following
membrane fusion M protein is released from the RNP with subsequent diffusion of M
into the cytoplasm and distribution of some of the released M to the nucleus of a host
cell. The studies in Chapter 2 investigated where in the endocytic pathway uncoating
occurs, where M is located following uncoating, and the role of the cytoskeleton in
distribution of input M by using a VSV, containing fluorescent M protein (rVSV-MLumio-Green). I found that uncoating occurs primarily in early endosomes and results in
the majority of M remaining associated with the endosomal membrane which eventually
localizes to the perinuclear recycling endosomes. A small fraction of M, which is
presumably released into the cytosol, gets delivered to the nuclear envelope, and I found
that the typical polymerized actin or microtubules within host cells were not required for
distribution of M to the nuclear envelope.
Uncoating and assembly of the VSV genome occurs on membranes within the
cytoplasm of the host cell. Exactly how both of these processes can occur in the same
environment (e.g. the cytoplasmically exposed membrane surface) without modification
of M protein by phosphorylation, cleavage, or some other change has been an intriguing
question in the field. In Chapter 3 I present results showing a pH effect on the M-LumioGreen protein fluorescence in vitro and during the endocytosis of virions which was
dependent on G protein. I also observed that low pH enhanced the release of M from
rVSV-wt virions, which suggested that acidification of the virus interior results in the
dissociation of M contacts within the virus enhancing the uncoating process.
An exposed protease-sensitive loop located between amino acids 120 to 129 of M
has been shown to be important for M protein self-association and has been proposed to
be crucial for assembly of virions. This knowledge comes from protease treated, purified
M protein and not from mutagenesis studies. In Chapter 4 I examined mutations in the
exposed loop and in particular a conserved aspartate at residue 125 of a conserved LXD
sequence. I found that virions with mutations at residue 123 or 125 of the LXD motif
have two phenotypes; 1) an assembly defect and 2) reduced viral protein synthesis
starting at 4 hours post infection. These two phenotypes have not been separated
genetically and the LXD motif may represent a motif of M involved in assembly and
support of VSV protein translation.
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Chapter 1: Introduction
Vesicular Stomatitis Virus (VSV)
Vesicular stomatitis virus (VSV): the prototype Rhabdovirus. VSV, is a
simple, enveloped, nonsegmented, negative-strand RNA virus in the family
Rhabdoviridae, and the order Mononegavirales. The Paramyxoviridae, Bornaviridae,
and Filoviridae families complete the order Mononegavirales. Virions from these four
families have a similar genome organization and share some properties of their
transcription, replication, and assembly.
The Rhabdoviridae family includes three genera: the Lyssavirus genus, which
includes rabies and the rabies-like viruses, the Emphemerovirus genus, which includes
bovine ephemeral fever virus (BEFV), and the Vesiculovirus genus, which includes VSV.
VSV, is the prototype virus from the Rhabdoviridae family, and has been a platform of
study for viral entry, transcription, replication, and assembly for many years. This is a
direct result of its simple genome, broad cell tropism, and ability to grow to high titers in
cell culture. There are two main serotypes of VSV found in the Western Hemisphere: the
Indiana and New Jersey serotypes. Outside of the laboratory, mammals, mosquitoes,
mites, and sand flies are among the hosts that can be infected by both serotypes. Of
particular importance is the economic impact of the disease it causes, vesiculo stomatitis,
in cattle, swine, and horses (121). This disease is characterized by vesicular lesions on
the hooves, teats, and gums of infected animals, which are similar characteristics to foot
and mouth disease. Though rare, VSV infections of humans can occur by accidental
exposure in the laboratory or contact with infected animals in rural areas (56). Infection
can result in flu-like symptoms for a few days, with vesicular lesions of the mouth, or no
symptoms at all.
While not a human pathogen, VSV is a member of an order with many important
human pathogens such as rabies virus, Ebola virus, Marburg virus, human parainfluenza
virus, respiratory syncytial virus, and measles virus. Because virions found in the
Mononegavirales share some aspects of their viral replication cycles, further insight into
VSV’s viral cycle can open a window to important information about the viral cycles of
the human pathogens in this order. In addition to being a model, recombinant VSVs
(rVSVs) are being tested as vaccine vectors and viral cytolytic vectors to fight certain
cancers and HIV infections (185, 193). Developing a clearer understanding of VSV’s
viral cycle could help make these vectors more effective and safe for use in humans.
A brief history of VSV in the Americas. The two main serotypes of VSV found
in the United States, the Indiana and New Jersey, were isolated in the 1920s. In 1925 a
shipment of cattle that arrived in Richmond, Indiana from Missouri developed vesicular
lesions in the mouth and were associated with an outbreak of vesicular stomatitis in the
area. Virions isolated from the lesions were able to infect horses and could be serially
1

passaged in animals. This virus then became the VS-Indiana strain (39). An outbreak of
vesicular stomatitis occurred among cattle in New Jersey during the year of 1926. The
agent responsible for this disease was found to be filterable and that it could infect cattle,
guinea pigs, and horses. However, it was found that this virus was serologically different
from the Indiana strain and became known as the VSV-New Jersey strain (38, 39). The
Indiana and New Jersey serotypes have been the most commonly isolated strains in the
Americas. In the United States, the last Indiana outbreak occurred in 1965 (96), whereas
New Jersey was responsible for outbreaks in the United States in 1944, 1949, 1957, 1959,
1963, 1982-83, 1985, 1995, 1997, 1998, and 2005 that were mainly located in the west
(1, 19, 143, 144). However, there is an island (Ossabaw) off of the coast of Georgia that
is the only known place to have VSV-New Jersey as an enzootic disease where it is
believed that a sand fly (Lutzomyia shannoni) on the island may be the vector that passes
the virus to the feral pigs, horses, deer, cattle and raccoons that inhabit it (191). Besides
the United States, VSV can also be found in other parts of the Americas including
southern Mexico, Central America, and northern South America where sporadic
epidemics emerge from the tropical areas (121).

VSV Composition and Replication
The composition of VSV. VSV is composed of an 11 Kb, negative-strand RNA
genome that contains five genes (3’-N-P-M-G-L-5’). These genes encode the
nucleocapsid protein (N), the phosphoprotein (P), the matrix protein (M), the
glycoprotein (G), and the large polymerase protein (L) (Fig. 1-1). The virion’s structure
is composed of a helical nucleocapsid, containing L-P-N-RNA-M, surrounded by a
membrane derived from an infected host cell membrane which has transmembrane
trimeric G proteins protruding from it. These bullet-shaped VSV particles are an average
of 180 nm long and 75 nm wide with around 400 trimeric G protein spikes on the exterior
of the viral membrane and about 1,800 molecules of M protein between the nucleocapsid
core and the viral membrane. The RNA genome is encapsidated by N protein with
around 1,200 molecules of this protein tightly complexed to the RNA like beads along a
string. The RNA-dependent RNA polymerase, consisting of the L and P proteins, is
associated with this ribonucleoprotein complex and these proteins are present at 50 and
500 molecules per virion, respectively. This L-P-N-RNA complex makes up the
ribonucleoprotein particle (RNP) which is coiled into a tightly packed helix of around 35
turns inside the viral membrane. The M protein condenses the RNP into this tightly
packed helix, which, when condensed as described, is referred to as the skeleton.
The viral replication cycle of VSV. VSV takes advantage of host cell machinery
to replicate. There are five stages involved in VSV replication that lead to progeny
virions. The first stage consists of adsorption of virions, via the G protein, to an
unidentified receptor on the host cell membrane and entering the cell through the
clathrin-mediated endocytic pathway (139). The second stage, uncoating, involves the

2

Figure 1-1. VSV schematic.
Electron Micrograph of VSV particles with a cartoon denoting viral proteins (note the
skeleton within the viral envelope of the cartoon) and their location within virions and an
SDS-PAGE gel. L, large polymerase protein, G, glycoprotein, P, phosphoprotein, N,
nucleocapsid protein, M, matrix protein. Illustration from the lab of Michael A. Whitt,
Ph.D. with permission from Clint Robison, Ph.D (personal communication).

3

pH-dependent fusion of the viral membrane with the endosomal membrane through the
activity of G protein which results in the release of the RNP core into the cytoplasm
where replication occurs (139). Either directly after or concomitant with membrane
fusion, M protein dissociates from the RNP core resulting in decondensation of the
skeleton, which when combined with membrane fusion results in completion of VSV
uncoating (130, 174). However, the trigger for M protein dissociation within a host cell
is unknown at this time. In the third stage, the decondensed, RNP serves as a template
for transcription of viral mRNAs by the packaged RNA-dependent RNA polymerase.
VSV transcription, like other nonsegmented negative strand RNA viruses, is sequential
and polar where each of the five genes is transcribed in the order that they appear from
the 3’ end of the genome (87, 88, 130). There is a ~30% reduction in the amount of
downstream message that is made when compared to the upstream message, resulting in
N mRNA being the most abundant message and L mRNA the least abundant (203). The
viral mRNAs are capped, methylated, and polyadenylated by the VSV polymerase (85,
186). Once primary transcription has occurred, stage four begins where the VSV
polymerase uses the same encapsidated genomic RNA as a template to synthesize a fulllength, anti-genomic replicative intermediate (RI). The RI functions as a template for
replication of more genomic RNA which can be used in subsequent rounds of
transcription, replication, and for packaging into progeny virions. Stage five involves the
assembly of the VSV virion which can be divided into three phases: (i) encapsidation of
newly made genomic RNA by the N protein and subsequent association of L and P
forming the RNP, (ii) condensation of RNP by the M protein and association with the
plasma membrane forming the skeleton, and (iii) budding from the host cell surface by
envelopment of the skeleton and then release of the progeny virion. The last two phases
of stage five are attributed to the activity of M protein (10, 67, 100, 130, 132, 153, 154).

The VSV Matrix (M) Protein
The M protein. M, the smallest of the virion’s proteins at 229 amino acids (26
KDa), is an unglycoslylated protein that is present at about 1800 copies per virion. It is
composed of a pleomorphic N terminus (residues 1-58) and a globular C terminus
(residues 59-229) made up of 7 beta sheets that “cap” three alpha helices (Fig. 1-2). The
M protein plays a key role in virus assembly and budding at the host cell’s plasma
membrane. It has the ability to bud vesicles from cells when it is expressed in the
absence of other VSV proteins (97), a property attributed to its PPxY (PY) motif that
binds WW domains of cellular proteins involved in multivesicular body formation (80).
Around 10% of VSV M is associated with membranes in infected cells, whereas the
remaining amount is cytoplasmic (30, 31, 146, 147) and nuclear (133). M protein, being
multifunctional, is also involved in the cytopathic effects inflicted on host cells infected
by the virus. These effects include inhibition of host mRNA expression (14), translation
(181) and nucleocytoplasmic transport (53), and the disruption of host cell cytoskeletal
organization (92). Over the past thirty years, many discoveries have been made
concerning M protein’s role in virus assembly and host cell cytopathic effects. However,
key questions still exist, including: what causes the matrix protein to dissociate, where

4

Figure 1-2. Crystal structure of the VSV M protein.
(A) Schematic of full-length M and the M proteins proteolytically cleaved by trypsin and
thermolysin, respectively. (B) Structure of the thermolysin cleaved globular core of the
M protein with 7 beta sheets surrounding 3 alpha helices also shown in (C). The exposed
loop is located at amino acids 120 to 129. Reprinted with permission from Marcel
Knossow, Gaudier, M., Y. Gaudin, and M. Knossow. 2002. Crystal structure of vesicular
stomatitis virus matrix protein. Embo J 21:2886-92, (66).
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does it distribute within cells during viral uncoating events, and which region(s) of M
interact during virion assembly?
M protein and membrane association. A fraction of M protein within infected
cells is associated with the inner leaflet of the plasma membrane (31). This localization
at the plasma membrane can occur even in the absence of other viral proteins. There are
no significant stretches of hydrophobic residues in the M protein that would serve as a
transmembrane region (120) nor are there any modifications by fatty acids to explain its
plasma membrane association. The N terminal region of M has been implicated in the
interaction with membranes via the hydrophobic, photo-reactive probe 125I-TID (120).
Also the N terminus of M contains a highly basic region which might be able to interact
with the negatively charged head groups of the membrane phospholipids by electrostatic
interactions. Though a logical assumption, deletion of the 43 residues in the N terminus,
which includes the basic region, only weakens membrane association and does not
completely reduce the interaction of M with membranes (30). This observation points to
perhaps another membrane interaction domain, which is speculated to be between
residues 88-119 (217) and/or a hydrophobic surface located close to a hydrophobic loop
that is surrounded by conserved basic residues (30, 66). VSV M cell membrane
association is necessary for its budding activity (119) and this activity is important for
virion release and hence virus assembly (91).
Formation of skeletons by M. Along with M association at the inner leaflet of
the plasma membrane, RNP condensation by M is also important in VSV assembly (132)
and this occurs at the plasma membrane (157). It has been shown that cytosolic and
membrane bound M can bind to RNPs but the proteins have a higher affinity for RNPs
isolated from virus versus cytosolic RNPs (57). These observations suggested that M
binding to RNPs is dependent on a change in cytosolic RNPs at the plasma membrane
and recent evidence has led to a model where G and RNPs associate in microdomains at
budding sites and then M is incorporated (195). Treating purified VSV virions with
detergent at low ionic strength solubilizes the viral membrane and G protein liberating
the highly condensed, tightly coiled skeleton which consists of the RNP and M protein
(153, 154). When these skeletons are placed in the presence of high ionic strength buffer
(~250mM NaCl) the result is decondensation of these compact structures by dissociation
of M protein. The decondensed RNPs can reform skeletons by dialyzing away the salt in
the presence of M protein. The association of M and subsequent condensation of RNPs
into skeletons results in an inhibition of viral transcription in vitro as well as in infected
cells (26, 44, 166). The N terminus of M is essential for binding to the nucleocapsid in
vitro (30, 158), but proteolytic cleavage of skeletons showed that the N terminus is
exposed to proteases when bound to nucleocapsids suggesting an indirect interaction
between this region and nucleocapsids (100).
Membrane associated M protein and its association with the glycoprotein (G)
protein. The G protein of VSV is incorporated into virions at budding sites along the
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plasma membrane and this has been shown to occur in microdomains that are not
detergent resistant (21) but that are enriched for sphingomyelin and cholesterol (111, 125,
126). It has been suggested that G is the protein that forms budding sites where the
internal viral components can then finish the process of forming a progeny virion (21). G
and M have been shown to interact within virions by chemical crosslinking experiments
(46) and within cells using fluorescence photobleaching assays which showed mutations
in the M protein have an effect on the mobility of the G protein on the surface of the cells
(173). Purified M protein and skeleton complexes were also shown to interact with and
stabilize G protein into trimers in in vitro assays (128). However, the amino acids of the
G protein cytoplasmic tail are not specific to this interaction. In fact the cytoplasmic tail
of G just needs to be 1 amino acid in length in order to be incorporated into VSV virions
(210). The ability to pseudo-type VSV with foreign glycoproteins also adds to the data
that suggests the interaction between G, M, and skeletons is a non-specific interaction
(184). Although VSV has a non-specific G cytoplasmic tail interaction in assembly, the
G cytoplasmic tail of rabies virus is important for incorporation into rabies virions (149).
This observation suggests the interaction between the cytoplasmic tails of each virion’s G
protein with their respective skeleton is different between these two viruses found in
Rhabdoviridae. Recently, it has been shown that G and N may interact and this
interaction allows for the RNP to associate with the M protein at the budding sites (195).

VSV Entry and Uncoating
Entry of enveloped viruses into the host cell. Virions must penetrate the host’s
cellular membrane to release their genomes and proteins into the cytosol where they gain
access to the host’s machinery to replicate. In the case of enveloped viruses, this
penetration into the host’s cytosol requires a membrane fusion event to take place, which
is accomplished by a fusion protein on the viral surface. The membrane that is penetrated
in this case can either be the plasma membrane or the membrane of an intracellular
organelle along an endocytic pathway.
It is known that enveloped viruses like Sendai virus and HIV-I have pHindependent fusion proteins and can therefore fuse on the surface of the cell (52, 141).
The pH-independent nature of fusion for these virions and others like them leads one to
assume that fusion only occurs at the plasma membrane but this is difficult to prove as
these virus particles are continuously taken up by endocytosis as well.
Overall a majority of enveloped virions enter the cell through the endocytic
pathway, giving them the ability to move further into the cell. This allows them to
bypass potential barriers and a crowded cytosol (135) using the cytoskeletal machinery
involved in endocytic vesicle movement (45) in order to penetrate the cell for replication.
Virions that enter the cell along the endocytic pathway like VSV and influenza, use the
decreasing pH of endocytic organelles as a trigger for fusion in order to penetrate the cell
(207).
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Uncoating of genomes after entry of enveloped viruses. Virions entering a cell
have highly condensed genomes protected by proteins. Before these particles can
replicate in a host cell, after fusion and entry, an uncoating event must occur. This
uncoating event is described as release of the viral genome in a form that is immediately
ready for replication (DNA viruses), transcription ((-) RNA viruses), or translation ((+)
RNA viruses). Typically, uncoating involves the dissociation of the proteins condensing
the genome. Once the genome has uncoated replication of the virus can begin and this
process is the opposite of what occurs to package the virus for release. Here lies the
dilemma for how a virus can accomplish these two distinct mechanisms for the same
protein.
Influenza virus is the best example of how a virus can accomplish this through
virus-host interactions. As influenza virus is taken into the cell by endocytosis, the virus
encounters decreasing pH the further it is along the pathway. The virus takes advantage
of this pH decrease in another manner that is not linked with the pH-dependent fusion
during entry. Within its viral membrane there is an integral membrane protein called M2
that acts as an ion channel that shuttles the protons in the endosome into the virus (110,
169). In turn the acidification within the virion facilitates the dissociation of the M1
protein away from the viral RNPs of influenza virus (24, 222) resulting in enhanced
uncoating. This is a fascinating, yet simple approach for a virus to achieve the uncoating
dilemma by taking advantage of the different environments during the entry pathway.
VSV and the uncoating dilemma. VSV faces the same intriguing question
about what is responsible for the dissociation of M protein from RNPs. Unlike influenza
virus, VSV lacks an ion channel protein although previous studies have found at low pH
spike proteins of enveloped viruses such as VSV, Sindbis virus, and Semliki Forest virus
can make the viral envelope permeable to propidium iodide (101, 114). Also, cells
expressing these proteins on the cell surface show a pH-dependent permeability (101,
114). These observations coupled with the knowledge of how influenza virus uncoats
would lead one to believe that protons may be able to cross the viral envelope and affect
M in a manner similar to M1. However, in vitro studies did not discover a pH effect on
the M protein associated with skeletons (130). Instead it was suggested that dissociation
of M protein from skeletons occurs spontaneously as a result of the lack of M protein in
the cytosol since it was observed that association and dissociation of M at physiological
ionic strength with RNPs isolated from cells had characteristics of a dynamic reversible
equilibrium (130). The very idea that protons may cross the viral envelope is still an
intriguing concept considering that there are at least two populations of M (membrane
and RNP bound) within the virus. The skeleton associated M has been investigated in
previous studies but the effect of pH on M within the whole virion has not, which leads to
an interesting aspect to examine, namely whether VSV may employ a similar strategy as
influenza virus. This strategy may be similar for many of the enveloped virions that use
the endocytic pathway for entry.
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M in VSV Assembly
Budding of VSV progeny from host cells. Enveloped, negative-strand RNA
viruses have proteins with late domain motifs that are involved in recruiting the cellular
vacuolar protein sorting machinery to bud progeny virions from the host cell. Examples
include the gag proteins of retroviruses (165), the Ebola virus VP40 protein (12), rabies
virus M protein (80), and VSV M protein (80). These proteins contain either PS/TAP or
PPxY (PY) motifs that recruit WW containing ubiquitin ligases used in the cellular
fission machinery and/or the ESCRT-I complex (78, 103, 194, 201). VSV has both the
PPPY and PSAP motifs at the N-terminus of M, where the PY motif has been shown to
be important for budding activity (80, 91). The PSAP motif has not been shown to have
a major late domain role, but mutations in this region led to attenuation of virus both in
vitro and in vivo (86).
M protein and nucleocapsid condensation. As discussed previously, the
condensation of RNPs by M protein is a reversible process. Despite the fact that the
cytoplasm of VSV infected cells contains high concentrations of both intracellular RNPs
and soluble M protein, the two do not colocalize with one another (133, 160). The
plasma membrane is where M and RNPs interact with each other, suggesting that
condensation of RNPs does not begin until they associate with the membranes right
before budding (146, 157). Also, it has been proposed that an additional priming event is
needed in order to initiate the assembly process and may involve specific M nucleation
sites (67) or modification of the RNPs by viral or host factors (57, 130, 195).
The exact location of M within virions is a controversial topic at this time. The
general consensus is that M binds to RNPs and condenses them into skeletons (44, 153,
154). Whether M is inside and/or outside the skeleton is still not clearly defined. The
traditional view point is that M acts as a bridge between the nucleocapsid and the viral
membrane; putting it on the outside of the RNP (157, 162, 220, 221). Another point of
view is that M protein may form a rod-like scaffold around which the nucleocapsid is
wound (10, 11). A more detailed analysis of the virion’s structure is needed before one
or both of these ideas are accepted. It is clear though that there are two populations
inside the virion, the membrane and RNP bound forms. M protein has the ability to selfassociate: purified M protein was found to be a monomer in high ionic conditions
(500mM NaCl) in the absence of detergent, and in aggregates in low ionic conditions
(<200mM NaCl) (147). This self-association under low salt conditions was reversible by
treatment with Triton X-100 (147), suggesting that a hydrophobic interaction is involved
along with electrostatic interactions seen under the different ionic strength conditions.
Furthermore, nucleation sites have been implicated in the ability of M to self-associate,
where the N terminus is important for the creation of these nucleation sites and an
exposed loop in the C terminus is important for recruitment into these sites (65, 67).
Biophysical studies and electron microscopy have shown the aggregates of M to be rodlike in shape and to have similar striations like those found in skeletons (67). Suggesting
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that the aggregates have similar morphological features when compared to skeletons and
that the exposed loop is important for the assembly of VSV.
Self-association of VSV M protein. The protease-sensitive exposed loop,
located between amino acids 120-129, of the M protein has been implicated in virion
assembly, specifically in regard to M self-association (66). Cleavage of this loop with the
protease thermolysin results in M that cannot self-associate. In fact, M self-association
was an obstacle in the crystallization of the protein. It was found that cleavage by
thermolysin prevented self-association and allowed diffractable crystals to form (66).
This cleavage site was different from trypsin sites (loss of pleiomorphic N-terminus) on
M and was found to be between amino acids 120-PAVLADQGQP-129 (65). Full-length
M (M), M cleaved by trypsin (Mt), and M cleaved by thermolysin (Mth) were studied and
found to have a decrease in the ability to self-associate in the order M>Mt>Mth (65). This
exposed loop is also believed to be involved in association of matrix with the plasma
membrane, which is where the matrix protein condenses the RNP into a skeleton (66,
157). The crystal structure of the Mth globular C-terminus revealed that there are seven β
sheets that cover three core α helices like a “turtle shell” (66). The loop is located on the
exterior (thermolysin cleavage) between a large and small β sheet that leads to one of the
core α helices (66). Mutations in the loop at amino acids 121 to 124 have been studied
and were found to have a minor effect on VSV assembly, and also infection of cells with
this virus resulted in reduced viral protein synthesis at 6 to 8 hours post infection (35).

VSV Cytopathogenicity and Methionine 51 of M
Leader RNA transcripts. VSV infection causes a range of cytopathic effects
from the shut down of host protein synthesis to the rounding of the cell at later times post
infection (138). Two products involved in inhibition of protein and RNA synthesis were
implicated in ultraviolet (UV) mapping experiments of which one was the leader RNA
transcript (48, 71, 206). The leader transcript is 45 nucleotides long and is transcribed
from the 3’ end of VSV’s genome before viral mRNAs are made. The role of the leader
RNA transcript in RNA synthesis inhibition has been implicated by observations that
revealed leader transcripts could be found in the nucleus of a host cell shortly after
infection (108), that leader RNA could associate with La protein, a putative RNA
polymerase III transcription factor (175), and that leader RNA could inhibit transcription
of RNA by the RNA polymerase II and III enzymes in HeLa cell extracts (72, 73, 148).
It must also be said that leader RNA on its own was shown to be insufficient to inhibit
host transcription, where a host factor or viral protein(s) may be required for the
inhibition (47, 170).
Inhibition of host gene expression by M protein. The viral protein required to
inhibit host transcription was found to be M by in vitro and in vivo studies. Within
infected cells the M protein is found in the nucleus (133), and the expression of the

10

protein alone in the absence of other viral components results in the inhibition of host
directed gene expression (14). In fact, it is difficult to express M from vectors that rely
on the host cell transcription machinery (16, 122). Inhibition of transcription by M was
shown to be very effective, where it reduced the amount of gene reporter expression by
50% with 1,000 fold less protein present than the amount found in host cells between 4
and 6 hours post infection (131). M protein has been shown to reduce expression from
the IFNβ promoter (55), which was correlated with inhibition of RNA transcription and
protein translation (4). The inhibition of transcription has been linked to interference
with RNA polymerase II in a non-promoter-dependent manner and RNA polymerase III
in a promoter-dependent manner (3). It has also been shown that M interferes with
transcription factor (TF) IID but most likely in an indirect manner as M could not
interfere with TFIID in an RNA polymerase II in vitro transcription assay (218, 219).
The inhibition of host gene expression was found to be genetically separable from
the assembly functions of M. In a study of the temperature-sensitive (ts) mutant tsO82,
where M has a M51R mutation and is defective in its ability to inhibit host gene
expression, it was shown that ts082 could rescue a group III M mutant tsO23 virus that is
defective in assembly (15). This separation of host gene expression inhibition and
assembly activity was also shown by observing the MN1 deletion mutant, lacking amino
acids 4-21 at the N-terminus, which was assembly defective but was still able to function
in inhibition of gene expression (15).
Inhibition of nucleocytoplasmic transport by M protein: implications for
methionine 51. The M protein has multiple cytopathic effects on the host cell and in
addition to the inhibition of transcription it can inhibit nucleocytoplasmic transport of
host mRNA when the protein is expressed in cells (168). In Xenopus laevis oocytes, M
inhibited the import of snRNPs and karyophillic proteins as well as export of snRNAs
(60) and mRNAs but not tRNAs (168). This block of transport was shown to inhibit
snRNA processing and assembly within 1 hour of infection and may be the first
cytopathic effect by VSV (60).
The inhibition of nucleocytoplasmic transport by the M protein has been shown to
be through the interaction with RaeI and the nucleoporin Nup98 at the nuclear pore
complex (NPC) (53, 204). The region on the M protein that is responsible for this
interaction has been mapped to amino acids 51-59 with methionine 51 (M51) being the
most important for colocalization to NPCs and inhibition of nucleocytoplasmic transport
(168). Recently, it was also shown that the VSV New Jersey M48 and M51 residues are
important for inhibiting gene expression, suggesting that these may be involved in a
similar mechanism for this M protein (104).
The M51 residue and its role in nucleocytoplasmic transport inhibition has been
put to the forefront of oncolytic therapy with VSV (50, 109, 127, 193). It was shown that
attenuated VSVs with a deletion or mutations at the M51 residue were able to exploit the
inability of oncogenic cells to respond to interferon, leading to infection and oncolysis.
While the cells cannot respond to interferon, they can make interferon and this leads to
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protection of cells that can respond to interferon in vivo (192, 193). This is the basis for
oncolytic therapy at the present time and will be a part of the future of VSV as an
oncolytic vector (8, 9, 36, 49, 62, 127, 156, 171, 188, 213, 214).
Cell rounding: as a hallmark of VSV infection. A characteristic of wild-type
VSV infections is the loss of a cell’s normal morphology resulting in cells that become
round (155, 217). This ability to round the cells has been attributed to the M protein (16)
and the sequential disassembly of the cytoskeleton (190). It was also shown that M
protein could co-immunoprecipitate with tubulin from infected cell extracts and that M
could interact with polymerized and disassembled tubulin in vitro (150). In these studies
it was suggested that the highly basic N-terminus was important for this effect as
proteolytically cleaved M did not associate with tubulin as well in vitro and this
interaction was indicated through the acidic C-terminus of tubulin (150). This suggestion
does not correlate with data from cells expressing the deletion mutant MN1, which is
missing amino acids 4-21 and therefore the highly basic region, which lost their
morphology and became round (129).
The tsO82 M51R mutation in M protein on the other hand affected the ability to
cause the dissociation of the cytoskeleton in cells expressing that protein (129). This
observation correlates with data that suggested two additional translation products from
the M gene, called M2 and M3, were important for the cell rounding phenotype of the M
protein (92). It was found that these products were the result of downstream methionines
in the same open reading frame as full-length M, at methionines 33 and 51. When these
residues were mutated to alanines (M-33,51A) the translation of M2 and M3 was
abolished and cell rounding was delayed without affecting virus assembly. Transient
expression of M2 and M3 was sufficient to cause cell rounding and expression of these
proteins from a separate cistron in a virus that expressed M-33,51A restored cell
rounding, suggesting these two translation products are required for cell rounding (92).
These data taken together with the M51R M mutant data suggest that not only is the
methionine 51 residue important for inhibition of nucleocytoplasmic transport but also as
a start site for a polypeptide of M that contains amino acids 51-229. One could imagine a
scenario where this offers VSV an advantage of having different populations of M: (1) a
population with the N-terminal amino acids important for membrane binding and
budding activity that is used for assembly of progeny virions and (2) a population without
those amino acids that cannot be sequestered to the cellular membranes as readily and
therefore could interact with NPCs and cause other cytopathic effects. Not only has this
been shown for VSV Indiana M protein but it has recently been shown that methionines
48 and 51 of the VSV New Jersey M protein have similar requirements for CPE (104).
M protein and apoptosis. It was found that VSV infection in HeLa cells resulted
in fragmentation of chromosomal DNA into nucleosomal oligomers and in nuclear
fragmentation, which are cell effects usually associated with apoptosis (107). In fact, it
was shown that expression of the M protein from mRNA within HeLa and BHK cells
could induce apoptosis because the cells underwent morphological changes and caspase-3
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was activated (106). It was also suggested that the cell rounding ability of M was a result
of apoptotic activity (105). Comparison of wild-type M and the M51R mutant revealed
that these proteins could induce apoptosis differently where wild-type used the
mitochondrial induced pathway and was shown to be sensitive to over expression of Bcl2 (63). In contrast, the M51R mutant could induce apoptosis through the death receptor
pathway and required activation of caspase-8 (63) through PKR, Fas, and Daxx signaling
(62).

Enveloped RNA Viruses: Origins and M Proteins
Origin and evolution of RNA viruses. The origin of “the ancestor” nsRNA
virus and the relationship between this ancestral virus and present day virions that are
continually evolving is a topic that is not easily addressed. Unlike the evolutionary study
of animals and plants, there is no fossil record of their existence over billions of years.
All that can be studied are the genomes and their products, the replication strategies, and
host ranges of viruses to make any inference about where they may have originated in
terms of evolution. Based on these observations viruses have been classified by either the
International Committee on Taxonomy of Viruses (ICTV) or by the Baltimore
classification system (7, 140). Evolution is a consequence of the reproductive success of
individuals and their phenotypes that have an influence on the subsequent genotypes that
occur from generation to generation. Due to their self-replication and polymerase fidelity
mutations can occur that increase the fitness of nsRNA viruses. The escape from host
antiviral responses by HIV-I (37) and changes in host range by influenza A (205) are a
few of the examples of the evolution of some RNA viruses whether they be short or long
term changes.
M proteins of enveloped RNA viruses. Enveloped RNA viruses use M proteins
to condense RNPs and to link RNPs to the virus membrane. In the case of retroviruses,
which have a precursor gag polyprotein consisting of the matrix (MA), capsid (CA), and
nucleocapsid (NC) proteins, the CA protein condenses the genome and the MA is
responsible for RNP association with the virus membrane. Though similar in function,
the sequence homology of the M proteins from filo-, rhabdo-, myxo-, and paramyxovirus
and retroviral MA do not show clear homology although the L domains of PS/TAP or PY
motifs are similar in these proteins that function in budding of virions from host cells (40,
79, 80, 119, 216). Comparison of the structural homology has been examined by
structural biologists in reviews of the literature between Ebola virus VP40, VSV M, and
HIV MA and these were found to have no structural homology (200), but a comparison
between influenza virus M1 and HIV MA and CA proteins revealed that the M1 protein
may have a combination of the important structural assembly elements of the MA and
CA proteins (77). Taken together these observations show that trying to find the
evolutionary link between proteins from RNA viruses is a complicated endeavor.
Proteins that have the same function can just be a result of necessary functions needed to
release protected genomes from cells so the virus has acquired (or evolved) a protein for
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this function. Alternatively, these proteins may have structures that have arisen for the
functions suggesting modular evolution.

Hypotheses
Hypothesis 1. Based on the literature discussed in this introduction, the first
hypothesis investigated in this dissertation is that VSV uses host cell factors/processes for
dissociation and distribution of the matrix protein during uncoating (Chapters 2 and 3).
The areas of investigation for this hypothesis are indicated by (1) and (2) respectively, in
Figure 1-3.
Hypothesis 2. The second hypothesis investigated is that the amino acid
sequence of the exposed protease-sensitive loop of the M protein is important for VSV
assembly (Chapter 4) at the site indicated by (3) in Figure 1-3.
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Figure 1-3. Hypotheses model.
(1) Location within the VSV entry pathway where the question of what cellular factor is
involved in uncoating will be addressed. (2) After dissociation of M from RNPs what
cellular processes are involved in M distribution? (3) Location in assembly of VSV
where the question of the amino acids in the protease-sensitive loop will be examined.
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Chapter 2: Analysis of Matrix Protein Distribution after
Vesicular Stomatitis Virus Uncoating
Introduction
Entry of enveloped viruses through the clathrin-mediated endocytosis pathway
generally occurs by attachment to the cell surface and uptake of virions in coated vesicles
that are transported through the endosomal pathway to early or late endosomes. At early
or late endosomes there is a pH induced fusion of the endosomal and viral membrane,
which results in virus uncoating and release of the genome (114, 136). Vesicular
stomatitis virus (VSV), a prototype enveloped, nonsegmented, negative-strand RNA virus
in the family Rhabdoviridae, enters the host cell through this pH-dependent endocytic
pathway (139). VSV’s genome encodes five major viral proteins: the nucleocapsid
protein (N), the phosphoprotein (P), the matrix protein (M), the glycoprotein (G), and the
large polymerase protein (L). The viral genome is encapsidated by the N protein and
associates with the viral RNA-dependent RNA polymerase (complexes of L and P
proteins), which together form the ribonucleoprotein (RNP) complex. The M protein
within virions is associated with RNPs in structures called skeletons (153, 154) and a
separate membrane associated population of M anchors the skeletons to the viral
membrane (31, 151), which has transmembrane G protein spikes that protrude from the
membrane. The G protein is responsible for attachment of virions and fusion of the
endosomal and viral membranes (18, 82, 134, 161, 198, 211) and results in the transfer of
the genome into the cytoplasm where VSV replication occurs following fusion (139).
Either directly after or concomitant with membrane fusion, M protein dissociates from
the RNP core which results in the decondensation of the skeleton (153, 154) and
completes virus uncoating (174). After uncoating, the decondensed RNP serves as a
template for transcription of viral mRNAs by the packaged RNA-dependent RNA
polymerase.
Virus uncoating, defined as the dissociation of M from RNPs is an essential step
which is required for a productive infection (130); without this occurrence it is thought
that transcription of viral mRNAs will not proceed since it has been shown that
transcription from RNPs is inhibited by M protein (32, 44, 212). This essential step is
also shared by another enveloped negative-strand virus, influenza, which requires
removal of its matrix protein (M1) for a productive infection (102, 137). To better
understand this essential uncoating step, we wanted to develop a recombinant VSV
(rVSV) that would allow us to visualize the release of M protein in live cells.
Five different rVSVs encoding fluorescent M proteins were constructed for this
study. Three of these contained M fused to green fluorescent protein (GFP). This
strategy has been used to generate rVSVs that encoded fluorescent G (G-GFP) and P
(PeGFP) proteins which were used to examine virus entry and assembly (41, 42). In
previous studies, GFP has been fused to M at the N and C termini to observe M protein
expression, function, and localization in the absence of other viral proteins (69, 123, 168),
but these chimeric proteins were not studied in the context of virus assembly. Here we
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fused GFP to the C-terminus of M (MFC) to avoid the important regions on the Nterminus involved in membrane association (30, 31, 120, 217) and virus budding (80, 91).
Unexpectedly, the M-GFP chimeras had reduced budding activity when compared to M
wild-type (Mwt), and rVSVs that encoded MFCs as the sole M protein were unable to be
recovered; however virus encoding Mwt and MFC as an additional gene between G and
L (rVSV-M-MFC) was recovered, but the amount of MFC incorporated into virions was
low and we were unable to detect the virus bound to cells by fluorescence microscopy.
In an alternative approach we fused a tetracysteine (-CCRECC-) LumioTM tag to
M and recovered infectious virus. LumioTM technology has been used previously to
study Ebola VP40 membrane localization (164) and to label human immunodeficiency
virus-1 (HIV-1) integrase for live cell HIV-1 entry (5). Using in vivo labeling with
LumioTM Green and purification of labeled virus we visualized VSV entry and the
subsequent fate of M-Lumio-Green in fixed and live cells.
We show that after fusion of rVSV-M-Lumio-Green with endosomes, the bulk of
M-Lumio-Green remains associated with recycling endosomes but some also localizes to
the nuclear envelope. The delivery of M-Lumio-Green to the nuclear envelope was not
dependent on actin or tubulin suggesting this may occur by diffusion. Using confocal
microscopy we observed that RNPs physically separated from M-Lumio-Green on the
endosomal membrane and that the release of RNPs into the cytoplasm was also not
dependent on microtubules. We believe the release of RNPs seen after rVSV-M-LumioGreen virions have fused with endosomes is a measure of an uncoating event and
therefore defines the start of a productive infection for rVSV virions.

Materials and Methods
Plasmid design and construction. Construction of the cDNAs of MFC-II, -III,
and -IV (MFC) illustrated in Figure 2-1A was accomplished using pBluescript(BS) MΦT
(wild-type; Indiana) as a vector and overlapping PCR to fuse the N-terminus of GFP to
the C-terminus of M. Primers (GFP-M-C-Link-C, CEM 4, or 5) which had a 5’ NheI site
followed by sequences encoding an 8 (-II), 15 (-III), or 20 (-IV) amino acid (Gly-Ser)
linker that joined to the initiating methionine of GFP, were used together with a noncoding primer (GFP-NdeI-NC) to amplify a PCR fragment that served as a link between
M and GFP in a triple ligation of gel purified fragments. The M-GST cDNA was
constructed by fusing the N-terminus of GST to the C-terminus of M using an 8 amino
acid (Gly3-Ser)2 linker in a similar way but using the primer 5’GST-cod to join the linker
to the initiating methionine of glutathione-S-transferase.
pBS-M-Lumio was constructed by annealing two overlapping oligonucleotides
that encoded the tetracysteine (*) LumioTM tag (Fig. 2-1B, amino acids 230-246) to the Cterminus of M. A coding and non-coding oligonucucleotide (CEM6 and CEM7) that
encoded the amino acids in the tag were phosphorylated with T4 polynucleotide kinase
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Figure 2-1. Schematic of fluorescent M proteins and rVSV genomes.
(A) Depiction of the MFC protein and the organization of the rVSV-M-MFC genome. (B) Illustration of the Lumio-M and M-Lumio
proteins. Amino acid positions are designated by numbers and the amino acid sequence of the LumioTM tag (gray box) at the Cterminus is shown. The Lumio-M protein contains an initiating methionine on the N-terminus of the Lumio-tag. The cysteines that
bind the biarsenic LumioTM reagent are denoted by * symbols. The location of Lumio-M or M-Lumio in the viral genome is shown.
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and were annealed to form a linker with NheI and EagI overhangs, and used to ligate into
the vector pBS-M-Flag-C digested with NheI and EagI.
The pBS-Lumio-M plasmid was constructed by using PCR amplification of pBSMΦT as a template with a primer containing KpnI and AscI restriction sites, a Kozak
sequence (TTCATCATGG), and the sequence for the LumioTM tag at the 5’ end which
overlapped with the first 24 bp of the coding sequence of M (CEM8) and a 3’ reverse T3
primer. The product was digested with KpnI and EagI, gel purified, and ligated into pBSMΦT digested with the same enzymes. Sequences of constructed cDNAs were
determined by the Molecular Resources Center at the University of Tennessee Health
Sciences Center and no changes from predicted sequences were found.
Generation of full-length VSV cDNAs encoding MFC, M-GST, M-Lumio,
and Lumio-M. The MFC, M-GST, M-Lumio, and Lumio-M chimera sequences were
cloned into the polylinker (PL) of a modified version of the VSV anti-genome pΔM-PLF
(91) except there was no GFP between the G and L coding regions. The resulting
plasmids were called pVSV-MFC-II, -III, -IV, pVSV-M-GST, pVSV-Lumio-M, and
pVSV-Lumio-M. For rVSV plasmids encoding Mwt and the MFC chimeras together, the
cDNAs for MFC-II, -III, and -IV were cloned into the polylinker of pVSV-GL-PL (92)
located between the G and L genes.
Recovery and characterization of recombinant VSV (rVSV). Recombinant
viruses were recovered using reverse genetics (116) with some modifications as
described previously (91). Single-step growth curves were performed by adsorbing virus
to baby hamster kidney (BHK-21) cells in 35 mm plates at a multiplicity of infection
(MOI) of 10 for 1 hour at 31oC while continually rocking. The inoculum was removed,
the cells were washed 4x with serum-free Dulbecco’s minimal Eagle’s medium (DMEM)
to remove unbound virus, DMEM containing 5% fetal bovine serum (FBS) was added,
and the cells were placed at 37oC. Every two hours post infection (hpi) a 5% aliquot of
media was collected, replaced with the same volume of fresh media, and then virus titers
were determined in duplicate by plaque assay on BHK-21 cells. Growth curves were
performed in triplicate for each virus.
Transient expression of MFC, M-Lumio, and Lumio-M proteins. BHK-21
cells at ~90% confluency on glass cover slips in 35mm dishes, were infected with a
modified vaccinia virus (vTF7-3) encoding T7 RNA polymerase (61) at MOI 5 for 1 hour
at 31oC in SF-DMEM. The inoculum was removed and the cells were transfected with
5µg of pBS-MΦT (wild-type; Indiana), pBS-MFC-II, -III, or -IV, pBS-M-Lumio, or
pBS-Lumio-M using 20 µl TransfectACE in SF-DMEM (180). Five hours post
transfection (p.t.) the transfection mix was removed and replaced with 5% FBS DMEM
containing antibiotics (100U/ml streptomycin and penicillin), and 18 hours p.t. the cells
were fixed and processed for immunofluorescence or were used in a budding assay as
described below.
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Immunofluorescence (IF) staining and confocal microscopy. Cells either
transiently expressing M proteins from plasmids or infected with rVSV were washed
twice with phosphate-buffered saline (PBS) and then fixed for 15 minutes with 3%
paraformaldehyde (PFA) in PBS at room temperature (r.t.). The fix solution was then
removed and the cells washed twice with PBS containing 10 mM Glycine and 0.05%
sodium azide (PBS-Glycine), and then permeabilized with 1% Triton X-100 in PBSglycine at r.t. for 1 minute. After permeabilization, the cells were washed twice with
PBS-Glycine and then stained for; M protein using an anti-M monoclonal antibody (mAb
23H12) conjugated to rhodamine, VSV N protein using anti-N mAb 10G4 conjugated to
rhodamine, Nup62 using anti-Nup62 mAb (# 610497, BD Biosciences), mannose 6
phosphate receptor (M-6-P-R) using anti-M-6-P-R mAb (# MA1-066, Affinity
BioReagents), LAMP-1 using anti-LAMP-1 mAb (Developmental Studies Hybridoma
Bank at the University of Iowa), or microtubules using anti-α tubulin mAb (# A-11126,
Molecular Probes). The unconjugated primary antibodies were detected with a goat antimouse secondary antibody conjugated to rhodamine (Jackson Research Laboratories) or
for anti-Nup62 we used Zenon Goat anti-mouse IgG2b Alexa Fluor 647 (# A-21242
Invitrogen; Molecular Probes). Phalloidin conjugated to Texas Red-X (Invitrogen;
Molecular Probes) was used to stain actin. The distribution of the indicated proteins was
examined using laser scanning confocal microscopy (Zeiss LSM 510 AIM version 3.2
software). Optical slices of 1 µm were captured using 488nm, 543nm, and 633nm laser
excitation. Quantification for colocalization of M and N protein was accomplished using
the “Profile” function of the Zeiss LSM software by counting the number of N protein
foci that colocalized with M in a total of 50 cells from three different experiments.
Budding assays. Cells transiently expressing the indicated M protein were
washed twice with methionine-free, SF-DMEM and then incubated in this media for 15
minutes to deplete the intracellular methionine pools at 5 hours p.t. After depletion, a
media composed of 1 part 5% FBS DMEM to 9 parts methionine-free media and
supplemented with 50 µCi of 35S-Methionine (Met) Express Protein Labeling Mix
(Perkin-Elmer) per ml was added and 18 hours later media and cells were collected
separately and processed for immunoprecipitation (IP).
The media were centrifuged at 170 x g for 10 minutes to remove dislodged cells
and the supernatant was placed on ice after addition of 200U of aprotonin (U.S.
Biochemicals). The supernatant was made to 50mM Tris-HCl, 150mM NaCl, 0.1% NP40, 1mM EDTA, 20mM NaN3, 0.3% SDS, and radio-labeled M proteins were
immunoprecipitated with M mAb (23H12) overnight at 4oC and retrieved using
Pansorbin (#507861, CALBIOCHEM).
Cell extracts were prepared by washing the cells twice with PBS and then lysing
with 800 µl of detergent solution (10 mM Tris-HCl [pH 7.4], 66 mM EDTA, 0.4%
sodium deoxycholate, 1% Triton X-100, 0.05% NaN3) containing 200U/ml of aprotonin
for 5 minutes at r.t. on a rocker. The cell extract was collected, nuclei and insoluble
material removed by centrifugation at 10,000 x g for 5 minutes and a 200 µl aliquot of
the cell extract was made to 0.3% SDS and immunoprecipitated with M mAb (23H12)
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overnight at 4oC followed by Pansorbin retrieval. One-quarter of the radio-labeled M
proteins in the cell extract were compared to the amount released into the supernatant by
SDS polyacrylamide gel electrophoresis (PAGE) on a 9% polyacrylamide gel and
visualized by fluorography.
Immunoblot analysis of rVSV-wt and rVSV-M-MFC virions. To detect the
presence and location of M-wt and MFC within virions, 1 µg of protein (~1 x 107 PFU)
from purified rVSV-wt or rVSV-M-MFC was solubilized by 0.1% Triton X-100 TN
Buffer (10 mM Tris-HCl [pH 8.0], 150 mM NaCl) in a total volume of 1 ml or left
untreated. One ml of each solubilized virus preparation was then ultracentrifuged over 3.5
ml of a 20% sucrose cushion (10 mM Tris-HCl [pH 8.0], 150 mM NaCl) at 45,000 rpm
for 35 minutes in an AH-650 swinging bucket rotor (Sorvall). After centrifugation 1 ml
of the supernatant was collected and the proteins in this fraction were precipitated by
adding trichloroacetic acid (TCA) to a final concentration of 10%. Viral proteins in the
pellet (RNP fraction) and the supernatant were separated by SDS-PAGE on a 10%
polyacrylamide gel and then transferred to a polyvinylidene fluoride (PVDF)
microporous membrane (Immobilon-P; Millipore). Monoclonal antibodies to M (23H12)
and GFP (# MMS-118R Covance) were used to detect each protein followed by addition
of a goat anti-mouse antibody tagged with horseradish peroxidase (Jackson Research
Laboratories). Proteins were located using a chemiluminescence kit (Immobilon
Western; Millipore) according to the manufacturer’s instructions.
LumioTM Green labeling and quantification of rVSV. BHK-21 cells on 100
mm plates at ~95% confluency were infected with rVSV-wt, rVSV-M-Lumio, or ΔG-MLumio at MOI 1. The inoculum was removed after 1 hour, the cells were washed two
times with SF-DMEM and 10 ml of 5% FBS DMEM was added. At 4 hpi the cells were
washed twice with reduced-serum Opti-MEM I media (GIBCO) and replaced with 10 ml
of Opti-MEM I containing 200 nM LumioTM Green (Invitrogen). Eighteen hpi the
supernatant was collected and labeled virus was concentrated by centrifugation over a
20% sucrose cushion at 38,000 rpm in an SW41 swinging bucket rotor (Beckman) for 45
minutes. The viral pellet was resuspended on ice in 1 ml of 10% sucrose TN buffer.
Residual, unbound LumioTM Green reagent was removed from the resuspended virus
preparation by adding 100 µl aliquots to Sephadex G-50 (Fine) columns (Roche). The
void volume containing the virus was collected and stored at -80oC except for ΔG virions
which were used for experiments on the same day of preparation. Titers were determined
by standard plaque assay on BHK-21 cells and protein concentration was determined by a
BCA protein assay (Pierce) according to the manufacturer’s directions.
The amount of fluorescence in the virus suspensions was determined by adding
one microgram of viral protein to a cuvette that contained 3 ml of HMTN buffer (10 mM
HEPES, 10 mM MES, 10 mM Tris-HCl [pH 8.0], 150 mM NaCl) using a Perkin-Elmer
Luminescence Spectrometer (LS 50B). Protein-specific fluorescence was examined by
dissociating virus in SDS-PAGE sample buffer containing one-tenth the normal
concentration of β-mercaptoethanol. Viral proteins were resolved on an SDS-10%
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polyacrylamide gel and the gel was analyzed for fluorescent protein bands using a
STORM 860 fluorescence imager (480 nm) and Imagequant software (Molecular
Dynamics). The same gel that was scanned for fluorescence was processed for
immunoblot analysis using the anti-M antibody (23H12) and proteins were visualized as
described above.
Live-cell synchronized entry assay. BHK-21 cells plated onto 35 mm glass
bottomed culture dishes (MatTek Corporation) at 90% confluency were washed twice
with 2ml of ice-cold Opti-MEM I and then placed at 4oC for 10 minutes. Lumio-labeled
virus (MOI 50) and human transferrin conjugated to Texas Red (50 µg) were adsorbed
for 90 minutes in 100 µl ice-cold Opti-MEM I with rocking every 15 minutes at 4oC. To
initiate entry, the ice-cold inoculum was replaced with Opti-MEM pre-warmed to 37oC
and the cells were observed by laser scanning confocal microscopy on a heated stage set
to 37oC and equipped with an objective heating collar using 488nm and 543nm laser
excitation with identical offset, gain and detector settings for each time point. The nonentry time point (t-0) was examined following addition of 2 ml of ice-cold Opti-MEM I
on a stage at ambient temperature. To reduce problems of sample photobleaching,
separate plates were examined for each of the time points (t-10, t-15, t-20, t-25, and t-30).
Synchronized fusion assay. To prevent the acidification of endosomes and
synchronize fusion of virions with endosomal membranes we used the lysosomotropic
reagent NH4Cl as described previously (174) with some modifications. BHK-21 cells on
coverslips were washed twice with PBS and then washed twice with PBS containing
100mM NH4Cl. Viruses (MOI 50-100) either with or without 50 µg of transferrin-TR
were adsorbed in SF-DMEM containing 100mM NH4Cl for 60 or 90 minutes. After
adsorption the cells were washed with PBS four times to remove the NH4Cl and were
either fixed with 3% PFA (t-0), or 2 ml of SF-DMEM at 370C containing 10μg/ml
cycloheximide was added for 60 minutes (t-60) and then fixed. Synchronized fusion
assays using the cytoskeletal inhibitors cytochalasin D or nocodazole were performed as
above, except virus was adsorbed for 60 minutes in media with 100mM NH4Cl and the
medium was replaced with SF-DMEM containing 10μM of the inhibitor and 100mM
NH4Cl and incubated for 30 minutes. The NH4Cl was then washed out as described
above but the cytoskeletal inhibitors remained for 60 or 120 minutes post lysosomotropic
washout (t-60 or 120) and the cells were fixed with 3% PFA and prepared for IF.

Results
Recovery and characterization of recombinant VSV encoding fluorescent M
proteins. To investigate virus uncoating and the fate of released M protein we
constructed two different types of M proteins with fluorescent tags. The first type
consisted of green fluorescent protein (GFP) fused to the C-terminus of M (Fig. 2-1A,
MFC). Three different MFC constructs were generated with linkers of 8 (Gly3-Ser)2
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(MFC-II), 15 (Gly4-Ser)3 (MFC-III), and 20 (Gly4-Ser)4 (MFC-IV) amino acids.
Previously others had reported the construction of M-GFP fusion proteins with GFP
fused at either the N- (69, 168, 204) or C-terminus (123) of M, but none of these
contained a linker separating M and GFP, which we reasoned may be important for
retaining the assembly function of M protein. We chose to fuse GFP at the C-terminus to
minimize interference with membrane association, which maps to the N-terminus of M
(30, 31). All three MFC proteins had identical intracellular distribution patterns when
examined by immunofluorescence microscopy (IF) which was indistinguishable from M
wild-type (wt) distribution (Fig. 2-2A).
To determine if the three MFC constructs retained the ability to bud vesicles when
expressed in cells (97) the amount of M released into the supernatant was examined.
Despite the normal intracellular distribution of the three MFC proteins, there was a
significant reduction in the amount of 35S-methionine labeled protein in supernatants
from cells expressing the MFCs (MFC-III shown) compared to cells expressing Mwt
(Fig. 2-2B lanes 3 and 2, respectively). To determine if the reduced budding activity was
due to a large C-terminal extension or was a specific GFP effect on budding activity, we
fused glutathione-S-transferase (GST) to the C-terminus of M (M-GST). Similar to the
results with the MFC proteins, we observed a large reduction in budding activity (Fig. 22B lane 4) even though there was no difference in cellular distribution of M-GST when
compared to Mwt (data not shown).
The low level budding activity of MFC and M-GST suggested that these proteins
might not be able to support virus assembly. Indeed, multiple attempts to recover rVSV
expressing any of the three MFC proteins or M-GST as the sole M protein were
unsuccessful (n = 6 per construct). However, we did recover rVSVs that expressed both
Mwt and the MFC proteins (rVSV-M-MFC, -II, -III, and -IV) from the same genome
(Fig. 2-1A). Characterization of these viruses showed that the growth kinetics were
similar to rVSV-wt (Fig. 2-2C, rVSV-M-MFC-III shown), however it was found that
MFC-III was incorporated at only 5% when compared to the amount of Mwt in rVSV-MMFC-III virions (Fig. 2-2D lane 4). When virions were solubilized with Triton X-100
and the RNP and envelope fractions examined, MFC-III was found mainly in the RNP
pellet fraction (Fig. 2-2D lanes 5 and 9). This result was unexpected since MFC-III was
seen at the plasma membrane of cells infected with rVSV-M-MFC-III (Fig. 2-2E,
arrows). To determine if the small amount of MFC-III incorporated into virions was
enough to detect in an uncoating assay, purified virus was bound to cells in the cold at a
multiplicity of 100. Cells were washed to remove unbound virus, fixed with
paraformaldehyde and then examined by fluorescence microscopy. Although virions
could be detected when the fixed cells were permeabilized and probed with an M
antibody, no GFP signal could be detected (data not shown). Considering the low
amount of MFC incorporation and lack of GFP signal when virions were bound to cells,
it was necessary to use an alternative strategy to make rVSV with fluorescent M protein.
The second type of fluorescent M protein we generated utilized LumioTM
technology, in which a tetracysteine (-CCRECC-) LumioTM tag (Fig. 2-1B) was fused to
the N or C-terminus of M (Lumio-M and M-Lumio, respectively). To assess the cellular
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Figure 2-2. Characterization of the MFC protein and rVSV-M-MFC virions.
(A) Laser scanning confocal microscopy of GFP, M-wt (Wt), and MFC-III expressed in
BHK-21 cells. Images are from 1 µm optical sections near the center of the cell where
GFP was detected using laser excitation at 488nm and M by staining with a M mAb
conjugated to rhodamine using 543nm excitation. (B) M protein budding assay. Cell
extracts and supernatants from cells infected with vTF7-3 alone (lane 1), or expressing
Mwt (lane 2), MFC-III (lane 3), or M-GST (lane 4) were immunoprecipitated with M
mAb after a 16 hour 35S-methionine labeling and examined by SDS-PAGE. (C) Growth
kinetics of rVSV-M-MFC and rVSV-wt. Aliquots of media were collected at the
indicated times post infection and titers were determined by plaque assay on BHK-21
cells. (D) Immunoblots of purified rVSV-wt (Wt) and rVSV-M-MFC (M-MFC) virus
(lanes 1 and 4) using a monoclonal anti-M antibody, or RNP (lanes 2 and 7, lanes 5 and
9) and TCA precipitated supernatants (lanes 3 and 8, lanes 6 and 10), after Triton X-100
solubilization of virus and ultracentrifugation over a 20% sucrose cushion, using anti-M
and anti-GFP monoclonal antibodies. (E) Localization of MFC in BHK-21 cells infected
with rVSV-M-MFC observed by confocal microscopy using laser excitation at 488nm at
8 hours post infection. Arrows show MFC associating with the plasma membrane of
cells.
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distribution and assembly function of these tagged proteins we compared them to M-wt
by IF (Fig. 2-3A) and in a budding assay (Fig. 2-3B). There was no discernable
difference between the distributions of the M proteins as they all were located in the
nucleus, were cytosolic, and localized to the plasma membrane (Fig. 2-3A). When
examined for budding activity, the N-terminally tagged Lumio-M showed a reduction in
the amount of protein released from cells (Fig. 2-3B lane 4) although not to the extent of
the MFC protein (Fig. 2-2B lane 3). The C-terminally tagged M-Lumio on the other
hand had wild-type budding activity (Fig 2-3B lane 6).
To determine if Lumio-M or M-Lumio could support virus assembly we replaced
the Mwt gene with the Lumio tagged versions in the viral genome (Fig. 2-1B). Both
viruses were easily recovered demonstrating that M proteins with small N or C terminal
tags are functional for virus replication and assembly. However, there was a growth
defect observed for the N-terminally tagged Lumio-M virus whereas the growth kinetics
of the virus with the C-terminally tagged M-Lumio virus was similar to rVSV-wt (Fig. 23C). Because the C-terminally tagged M-Lumio virus had growth properties
indistinguishable from rVSV-wt we used the rVSV-M-Lumio construct to make
fluorescent rVSV and for the uncoating studies described below.
Fluorescent labeling of rVSV-M-Lumio. LumioTM Green is a small (MW
664.5), membrane permeable fluorophore which fluoresces green when covalently bound
to the thiol pairs in the LumioTM tag (Fig. 2-1B, *) (2, 64, 70) . To fluorescently label the
rVSV-M-Lumio virus, we initially mixed purified virus with the LumioTM Green reagent
similar to that described by others to label HIV virions encoding a Lumio-tagged
integrase protein (5). However, in our case no labeling occurred suggesting that the
LumioTM tag was not available, or incapable of interacting with the fluorophore within
virions. We reasoned that the LumioTM tag may be more accessible for labeling within
cells before assembly into M-Lumio virions, therefore we added LumioTM Green to the
media of cells infected with rVSV-M-Lumio at 5 hours post infection (hpi). The
fluorophore containing media was removed one hour later and the cells were examined
by IF (Fig. 2-4A). We observed that the M-Lumio protein bound the fluorophore and the
labeling colocalized with M protein staining (Fig. 2-4A, merge). To produce fluorescent
virus, the fluorophore was added to infected cells at 4 hpi and the virus in the media was
harvested at 18 hpi. The labeled virus (rVSV-M-Lumio-Green) was concentrated by
ultracentrifugation through a sucrose cushion, resuspended in Tris-saline sucrose, and
passed through Sephadex G-50 columns to separate labeled virions from residual free
LumioTM reagent. The purified virions were titered and the amount of fluorescence
determined using a fluorometer. To examine relative infectivity of the labeled rVSV-MLumio-Green to a similarly prepared batch of rVSV-wt, we compared the protein profiles
from 1x107 PFU of rVSV-wt and rVSV-M-Lumio-Green after electrophoresis on SDSpolyacrylamide gels (Fig. 2-4B, left-hand gel). The slightly slower migration of MLumio compared to Mwt is due to the additional 17 amino acids of the LumioTM tag.
Coomassie-blue staining indicated the two virus preparations had similar amounts of
protein, but the rVSV-M-Lumio-Green had a 60-fold higher fluorescence signal than
rVSV-wt virus. To determine whether the fluorescent signal from the virions was due to
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Figure 2-3. Characterization of Lumio-M and M-Lumio and rVSV-MLumio/(Lumio-M) virions.
(A) Laser scanning confocal microscopy of M proteins expressed in BHK-21 cells and
stained with monoclonal anti-M antibody conjugated to rhodamine. (B) M protein
budding assay. Cell extracts (lanes 1, 3, and 5) and supernatants (lanes 2, 4, and 6) from
cells expressing Mwt, Lumio-M, and M-Lumio after a 16 hour 35S-methionine labeling,
immunoprecipitation with M mAb, and analysis by SDS-PAGE. (C) One-step growth
curve of rVSV-wt, rVSV-Lumio-M, and rVSV-M-Lumio.
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Figure 2-4. Labeling of rVSV-M-Lumio with LumioTM Green.
(A) Laser scanning confocal microscopy of BHK-21 cells infected with rVSV-M-Lumio
and labeled with LumioTM Green reagent for 1 hour at 6 hours post infection. (B) SDSPAGE analysis of 107 PFU rVSV-M-Lumio-Green and rVSV-wt virions. The left-hand
gel is stained with Coomassie blue. The relative fluorescence signal/µg is shown below
each lane. The center gel is an immunoblot for M (anti-M, lanes 1 and 2), and the righthand gel (lanes 3 and 4) was visualized by excitation at 480nm on a STORM
phosphorimager. Lanes 1 and 3 contain rVSV-M-Lumio and lanes 2 and 4 contain
rVSV-wt. The anti-M reactive and fluorescent bands at approximately 56 KDa are likely
artificially induced M-Lumio dimers formed as a result of the reduced concentration of βmercaptoethanol used in the sample buffer (see Methods for details).
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specific binding of the LumioTM reagent to the M-Lumio protein, we used a STORM
fluorescence imager (Molecular Dynamics) to visualize fluorescent proteins from
purified virus after separation by SDS-PAGE. Fluorescent protein bands were only
observed with the rVSV-M-Lumio virus and the bands that corresponded to fluorescent
M-Lumio protein were also detected in an immunoblot using an M-specific antibody
(Fig. 2-4B lanes 1 and 3, respectively). A higher molecular weight band was seen also in
the M-Lumio lanes by fluorescence and immunoblot analysis. This band corresponded to
an M-Lumio dimer and was the result of two conditions: i) the reduced amount of βmercaptoethanol in the protein sample buffer, which was required to retain the LumioTM
Green on the M-Lumio protein since increased reducing conditions results in the loss of
Lumio-Green binding (data not shown); and ii) the addition of four cysteines to M (wildtype has one cysteine at residue 135). Overall, these data demonstrated that rVSV-MLumio-Green was specifically labeled on the M protein and therefore should be useful to
examine virus uncoating and fate of M-Lumio-Green within cells.
Live-cell entry of rVSV-M-Lumio-Green. To follow the entry of rVSV-MLumio-Green virions into live cells, we adsorbed the virus (MOI 50) at 4oC for 90
minutes to prevent endocytosis of virions, and then initiated their entry by endocytosis
after addition of media at 37oC. Transferrin conjugated to Texas Red (transferrin-TR)
was used as an early and recycling endosomal marker during endocytosis of rVSV-MLumio-Green and both reagents were followed in 5 minute intervals over a 30 minute
time span, post addition of warm media (Fig. 2-5). Images for each time point were
acquired using identical detector settings to allow changes in fluorescence intensity to be
quantified. Figure 2-5 shows representative images of rVSV-M-Lumio-Green and
transferrin-TR at t-0 (top panels), t-5 (middle panels), and t-20 (bottom panels). At t-0,
rVSV-M-Lumio-Green and transferrin-TR were bound to the plasma membrane and
showed some colocalization. At t-5 (Fig. 2-5, t-5) both markers were internalized,
presumably in early endosomes. At t-20 (Fig. 2-5, t-20), the bulk of M-Lumio-Green
remained associated with perinuclear endosomes that colocalized with transferrin-TR
(Fig. 2-5, t-20 merge), while a fraction of M-Lumio-Green was found at what appeared to
be the nuclear envelope (Fig. 2-5, t-20 arrows). M-Lumio-Green could be detected on
the nuclear envelope as early as t-10 (data not shown), with increasing intensity up to t20, but there was no apparent gain in intensity of M-Lumio-Green fluorescence at the
nuclear envelope after 20 minutes post-entry. At no time did we observe transferrin-TR
associated with the nuclear envelope.
Synchronized fusion assay with rVSV-M-Lumio-Green. To examine the role
of new viral protein synthesis on the distribution of M-Lumio-Green after uncoating, we
synchronized viral fusion in the presence of cycloheximide as was done in a previous
study (174) with some modifications. rVSV-M-Lumio-Green virions (MOI 50) were
adsorbed to cells in the presence of NH4Cl to prevent acidification of endosomes and
thereby inhibiting fusion of endocytosed virions (82, 174). The inoculum and the
lysosomotropic agent were removed, the cells washed 4 times, and media containing
cycloheximide was added. Cells were then fixed at varying times post NH4Cl removal,
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Figure 2-5. Synchronized entry assay with rVSV-M-Lumio-Green.
Cells were inoculated with rVSV-M-Lumio-Green and transferrin-TR at 4oC for 90
minutes, and either fixed immediately with ice-cold 3% paraformaldehyde (t-0) or were
quickly warmed by the addition of 37oC media and examined by laser scanning confocal
microscopy. Images were collected every 5 minutes for 20 minutes using separate 35mm
glass bottomed dishes for each time point to reduce loss of signal by photobleaching.
(Top panels) Representative images of M-Lumio-Green and transferrin-TR at t-0 where
cells were fixed at 4oC, * represents the center of a cell. (Middle panels) Images
collected at 5 minutes (t-5) post addition of warm media. (Bottom panels) Images taken
at 20 minutes (t-20) after warm-up. Note the localization of M-Lumio-Green at the
nuclear envelope (arrows) and in perinuclear endosomes that colocalizes with transferrin.
Magnification 100X.
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stained with Nup62 antibody which binds to the nuclear pore complex (NPC) on the
nuclear envelope, and with an M mAb, and observed by IF. At t-0, rVSV-M-LumioGreen particles were in peripheral endosomes, similar to that found at the t-5 time point
in the live-cell synchronized entry assay (Fig. 2-6, t-0). At t-60, the bulk of M-LumioGreen was found in perinuclear endosomes (Fig. 2-6, t-60) and at the nuclear envelope
(arrows). Similar results were observed for rVSV-wt infected cells that were stained
using the M mAb (data not shown) except nuclear envelope staining was not detected by
the M mAb in either case (Fig. 2-6, t-60 center image) as this antibody binds to the site
on M required to bind at the NPC (168). Delivery of M-Lumio-Green to the nuclear
envelope was confirmed by colocalization with the nucleopore protein Nup62 (Fig. 2-6, t60 merge). These data showed that after NH4Cl washout M-Lumio-Green localized to
the nuclear envelope in the absence of new protein synthesis and therefore represents M
protein that is released into the cytoplasm and trafficked to the nucleus after uncoating.
The perinuclear endosomes associated with M-Lumio-Green colocalize with
transferrin-TR. M-Lumio-Green distribution was perinuclear by 15 to 20 minutes post
infection during synchronized entry of virus and at time points past t-20 (data not shown)
of the synchronized fusion assay. To determine the identity of these perinuclear
structures, we used markers that corresponded to lysosomes (LAMP-1), late
endosomes/lysosomes (Mannose-6-Phosphate receptor, M-6-P-R), and early/recycling
endosomes (transferrin-TR). We performed synchronized fusion assays with rVSV-MLumio-Green, as described above, and used monoclonal antibodies to label the cells for
LAMP-1 (Fig. 2-7A) and M-6-P-R (Fig. 2-7B), or visualized directly for transferrin-TR
(Fig. 2-7C). While some M-Lumio-Green colocalized with LAMP-1 (Fig. 2-7A) and M6-P-R (Fig. 2-7B) the majority of M-Lumio-Green colocalized with transferrin-TR (Fig.
2-7C). When images of the transferrin-TR endosomes that colocalized with M-LumioGreen were magnified (500X) the M-Lumio-Green was not evenly distributed throughout
the endosome, but instead appeared to be located on one side of the endosome (Fig. 2-7D
arrows). A similar distribution of M-Lumio-Green and transferrin-TR was observed for
images from the t-20 time point for synchronized entry (Fig. 2-5, t-20), which suggested
the results seen in figure 2-7C were not an artifact of lysosomotropic reagent treatment.
In contrast to the asymmetric distribution of rVSV-M-Lumio-Green in endosomes at t-60,
internalized ΔG-rVSV-M-Lumio-Green virions, which lack G protein and therefore
cannot fuse with the endosomal membrane, had a more diffuse distribution within the
transferrin-TR positive endosomes (Fig. 2-7E), suggesting the asymmetric localization of
M-Lumio-Green may represent virus that has fused and released its cargo. These data
indicate that even after 60 minutes most of the virus is not trafficked to late endosomes
and lysosomes, but remains in compartments that are thought to be the primary site of
virus uncoating.
Trafficking of M-Lumio-Green to perinuclear endosomes and the nuclear
envelope does not require actin or tubulin. To determine whether or not actin and
tubulin were required for delivery of M-Lumio-Green to the perinuclear endosomes at t60 or were required for delivery of M-Lumio-Green to the nuclear envelope, we treated
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Figure 2-6. Synchronized fusion assay with rVSV-M-Lumio-Green.
BHK cells were inoculated with rVSV-M-Lumio-Green at MOI 50 in the presence of
NH4Cl for 90 minutes to allow accumulation of virus in early endosomes. Entry was
initiated by incubation in media without NH4Cl, but containing cycloheximide. Cells
were fixed at t-0 (top panels) and t-60 (bottom panels), stained for M protein using a
rhodamine conjugated anti-M mAb (red) and Nup62 labeled with Alexa 647 (blue), and
examined by laser scanning confocal microscopy. Arrows indicate the localization of MLumio-Green at the nuclear envelope. Note the M mAb does not detect M protein
localized to the nuclear envelope. Magnification 200X.
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Figure 2-7. Identification of perinuclear structures associated with M-Lumio-Green
post fusion.
A synchronized fusion assay was performed as described for figure 2-6. Cells were fixed
at t-60 then stained for (A) LAMP1, (B) Mannose-6-Phosphate Receptor, or (C)
Transferrin-Texas Red and examined by confocal microscopy at 100X magnification.
(D) is at 500X magnification of perinuclear vesicles containing M-Lumio-Green and
transferrin-TR. Arrows indicate an asymmetric distribution of M-Lumio-Green within
transferrin-TR positive endosomes. (E) 500X magnification image of ΔG-rVSV-MLumio-Green inoculated cells showing transferrin-TR positive endosomes with a uniform
distribution of M-Lumio-Green within endosomes.

34

35

cells with the cytoskeletal inhibitors cytochalasin D or nocodazole in a modified
synchronized fusion assay. Cells were inoculated with virions in the presence of NH4Cl
for 60 minutes, and then the cytoskeletal inhibitors were added for the last 30 minutes of
a 90 minute incubation. After the 90 minutes of accumulation in early endosomes, the
cells were washed with media that either did or did not contain the cytoskeletal inhibitors,
and that also contained cycloheximide. At t-60 the cells were fixed and stained for
filamentous actin, using Texas Red-X phalloidin (Fig. 2-8) or for tubulin (Fig. 2-9).
Either in the absence (Fig. 2-8, top panels) or presence of cytochalasin D (Fig. 2-8,
bottom panels) after NH4Cl wash out M-Lumio-Green was found in perinuclear
endosomes and at the nuclear envelope (Fig. 2-8, arrows). When cells were treated with
nocodazole to determine the involvement of microtubules in M-Lumio-Green distribution
to the perinuclear region and nuclear envelope, we observed a reduction in the tight
perinuclear localization of endosomes containing M-Lumio-Green (Fig. 2-9, top versus
bottom panels), but the treatment did not prevent the association of M-Lumio-Green with
the nuclear envelope (Fig.2-9, arrows bottom panels). These results suggest that delivery
of M-Lumio-Green to the nuclear envelope does not require intact actin or microtubules.
Decrease in colocalization of M-Lumio-Green and N correlates with
productive infection and does not require tubulin. To determine if the M-LumioGreen nuclear envelope distribution was a result of uncoating, we assessed whether or not
we could detect M-Lumio-Green physically separating from nucleocapsids by observing
a decrease in colocalization of M-Lumio-Green and N using N mAb conjugated to
rhodamine in the presence of nocodazole and cycloheximide. rVSV-M-Lumio-Green
(MOI 100) was endocytosed into cells in the presence of NH4Cl and nocodazole and the
cells were observed at t-0 (Fig. 2-10A) and t-120 post NH4Cl washout, either in the
presence of nocodazole and cycloheximide (Fig. 2-10B), or in media that contained only
nocodazole (Fig. 2-10C). At t-0, Figure 2-10A shows there was 92.8% (+/- 3.4%, n = 50
cells) colocalization of M and N, whereas at t-120 (Fig. 2-10B) most of the M had
separated from the nucleocapsids as indicated by only 31.3% (+/- 8.2%, n = 50 cells)
colocalization (Fig. 2-10B). As previously reported by others (42), we also observed that
rVSV-M-Lumio-Green established a productive infection without an organized
microtubule network (Fig. 2-10C). These results suggest that the physical separation of
M-Lumio-Green from N protein observed by confocal microscopy represents the end
result of an uncoating event which can lead to a productive infection, and that this
uncoating event does not require an intact microtubule network.

Discussion
Recently visualization within live cells of Ebola VP40 (164) and HIV-1 integrase
(5) has been reported using a fluorescent LumioTM technology developed within the last
decade (2, 70). Fluorescently tagged viral proteins using GFP to study entry dynamics
and intracellular trafficking of HIV-1 (25, 152) and VSV (41, 42, 202) have also been
used. Although the G (41, 202) and P (42) proteins of VSV have been fluorescently
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Figure 2-8. Distribution of M-Lumio-Green in the presence of cytochalasin D.
(Top panels) Representative images of fixed cells from t-60 of a synchronized fusion
assay showing distribution of M-Lumio-Green, actin, and Nup62. (Bottom panels) The
same experiment and labeling as above except the cells were treated with cytochalasin D
for 30 minutes before NH4Cl washout and cytochalasin D remained in the post washout
media until cells were fixed 60 minutes later. Arrows indicate nuclear envelope
localization. For all the images in this figure signal levels were enhanced using Canvas
11 software to maximize the Lumio-Green signal after conversion to grayscale (A and B).
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Figure 2-9. Distribution of M-Lumio-Green in the presence of nocodazole.
(Top panels) Representative images of fixed cells from t-60 of a synchronized fusion
assay showing M-Lumio-Green, tubulin, and Nup62. (Bottom panels) The same
experiment and labeling as in the top panels except the cells were treated with nocodazole
to depolymerize microtubules for 30 minutes before NH4Cl washout and cells were
maintained in the presence of nocodazole until the cells were fixed at t-60. Arrows
indicate nuclear envelope localization. For all the images in this figure signal levels were
enhanced using Canvas 11 software to maximize the Lumio-Green signal after
conversion to grayscale (A and B).
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Figure 2-10. Release of RNPs from M-Lumio endosomes and productive infection
in the presence of nocodazole.
Representative confocal images of cells inoculated with
rVSV-M Lumio-Green (MOI 100) at t-0 (A) and t-120 (B and C), post NH4Cl
washout, in the presence of cycloheximide and nocodazole (B) or just
nocodazole (C), and stained for VSV N protein using N mAb conjugated to rhodamine.
Colocalization of M and N was measured post fusion using the colocalization function in
the LSM software version 3.2 and the percent colocalization of (M/N) is indicated for t-0
(A) and t-120 (B).
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tagged with GFP and studied, there have been no reports of fluorescently tagged M
proteins within virions for the study of M’s fate after entry. Here we report the
development and characterization of rVSVs with fluorescently tagged M using GFP
(rVSV-M-MFC) and LumioTM technology (rVSV-M-Lumio-Green). rVSV-M-LumioGreen was the best of these two virions for entry studies where the fate of the M-LumioGreen protein could be followed without the need for antibodies and due to epitope
restriction in previous studies could be seen for the first time at the nuclear envelope after
entry (Fig. 2-6, bottom panel arrows).
Previously, the M protein was fused to GFP and GST to study the
nucleocytoplasmic transport, nuclear localization signal (69, 168, 204), and
mitochondrial localization (123) of the M protein. Except for the mitochondrial
localization study (123), the majority of these fusions were at the N-terminus. However,
the effect of these M fusions on assembly of VSV virions was not examined. In these
studies the N and C-terminal fusions did not affect the M activity studied (69, 123, 168).
However, the N-terminus of the M protein is important in the assembly of virions as this
portion of the protein contains the membrane association region (30, 31, 120, 217) and
the PY motif (80, 91). In particular, membrane associated M has been shown to be
important for binding RNPs to the membrane and is thought to act as a bridge between
the membrane and RNP of virions (30, 31). In addition, the PY motif at the N-terminus
of M is important for budding activity and therefore budding of virions from the host cell
(80, 91). With this in mind we fused GFP to the C-terminus (Fig. 2-1A, MFC).
Surprisingly, we found that large C-terminal extensions, such as GST and GFP, can affect
M protein’s budding activity (Fig. 2-2B lanes 3 and 4) although there was no apparent
effect on M distribution to the plasma membrane (Fig. 2-2A). To our knowledge, this is
the first example of a fusion at the C-terminus of M affecting M’s budding activity,
whereas only N-terminal mutations have been previously shown to effect this activity
(91). Attempts to recover virions expressing MFC proteins (-II, -III, -IV, and M-GST as
well) as the sole M contributing to assembly were unsuccessful and we attributed this
failure to the inability of these proteins cause budding. We were able to recover rVSV
expressing both Mwt and MFCs and when the location of MFC within rVSV-M-MFC
virions was examined in Figure 2-2D, it was found to be associated mainly with the RNP
pellet (lane 9) versus the solubilized membrane fraction (lanes 10). This result showed
that MFC, despite the large C-terminal extension, associated with RNPs and was almost
excluded from the membrane of virions, which was surprising since MFC was clearly at
the plasma membrane of rVSV-M-MFC infected cells (Fig. 2-2E, arrows). Although the
majority of MFC within the virions was found with RNPs, it was only present at 5% of
the total M protein population. Assuming that each virus particle has approximately
1,800 molecules of M protein (199), rVSV-M-MFC virions would average around 90
molecules of MFC. Based on a previous report, this amount of GFP within the virions
may not be enough to visualize by microscopy since it was shown that 120 molecules of
eGFP were sufficient for detection of individual rotavirus particles (28) whereas PeGFP
virions (VSV-PeGFP) containing almost half of the 450 approximate copies of P per
nucleocapsid could be visualized under high magnification, live-cell microscopy (42).
The discrepancy between rVSV-M-MFC (~90 MFC copies) and VSV PeGFP (~225
PeGFP copies) virions could also be due to the inability of the GFP fused to M to
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undergo the proper conformational change to fluoresce. Also, there could be one
population of virions with high MFC content and others with hardly any MFC which
could lead to our inability to correlate plaque forming units (PFU) and percent MFC with
the expected fluorescence at laser excitation of 488nm, especially when one considers the
particle to PFU ratio of 1 to 200 (145) or 1 to 1,000 for VSV (unpublished lab data
comparing genomic RNA to PFU).
We were able to recover rVSV with fluorescent M using LumioTM technology
which utilizes a tetracysteine (-CCRECC-) motif that binds to membrane permeable
Lumio-fluorophores that fluoresce when bound to this motif (2, 70). We fused the
LumioTM tag to the N and C terminus of M and observed that the distribution of LumioM and M-Lumio was similar to Mwt and unlike the larger C-terminal extension of MFC,
M-Lumio with its smaller extension was able to retain a budding activity comparable to
Mwt (Fig. 2-3B lane 6), whereas Lumio-M was reduced in its budding activity (Fig. 2-3B
lane 4). Lumio-M or M-Lumio was able to support VSV assembly as the sole M protein
expressed from rVSV-M-Lumio genomes. Characterization of the growth kinetics of the
recombinants showed that rVSV-M-Lumio was the best virus to use of the two tagged
versions (Fig. 2-3C) and the protein to PFU ratio (Fig. 2-4B, left-hand gel) showed that
this construct was able to grow and incorporate other viral proteins to similar levels as
wild-type virus. The N-terminal tag results supported our original apprehension of fusing
a tag at that terminus. Next, we showed that M-Lumio could be labeled with LumioTM
Green (M-Lumio-Green) during infection and unlike the entry study involving the
labeling of HIV-1 integrase protein within virions with LumioTM reagent in vitro (5), we
could only label rVSV-M-Lumio virions within cells. Even though LumioTM Green is
membrane permeable, rVSV-M-Lumio virions were not able to be labeled in vitro and we
hypothesize that this may have to do with the compact nature of the M-Lumio within the
virion where the LumioTM tag is not accessible or cannot flex in order to bind to the
fluorophore.
In the synchronized entry assays, the bulk of M-Lumio-Green at 20 minutes post
warm-up was associated with perinuclear endosomes and a smaller proportion at the
nuclear envelope. This pattern was interesting as it was shown previously that ~15% of
input M could be found soluble within the cytosol after entry (174) and may account for
our observation that the bulk of input M is not in the cytosol. In the synchronized fusion
assays, we were able to show that M-Lumio-Green localized to the nuclear envelope after
fusion (Fig. 2-6, bottom panels). We believe the localization to the nuclear envelope is
indicative of M-Lumio-Green associating with nuclear pore complexes (NPCs), as the
localization is in the same area as Nup62 as shown by the blue staining in the merged
image of figure 2-6. We did not expect to see clear colocalization of the proteins since M
associates with RaeI and Nup98 at the NPCs (53) and not directly with Nup62. The
nuclear envelope association was similar to that of GFP-M association with NPCs as
shown in a study of M binding to NPCs (168). This same study reported that M is not
labeled by the monoclonal antibody (23H12) for M (Fig. 6, t-60, arrows, anti-MRhodamine), which recognizes the motif that binds to RaeI, and can prevent its binding
and localization to the NPCs (53, 168). Because we did not require antibody to visualize
M-Lumio-Green we were able to observe released M that was distributed to the nuclear
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envelope and to our knowledge this is the first reported observation of this type of
distribution after entry. We propose that upon VSV entry into host cells, released M
protein associates at the NPCs to block nucleocytoplasmic transport (84), giving the virus
an advantage over the host cell by blocking host cell mRNA transport (84) and thus the
innate immune response (193) before viral protein synthesis has begun.
To address what the M-Lumio-Green associated perinuclear bodies were, we
looked at markers for the endocytic pathway that corresponded to lysosomes, late
endosomes/lysosomes, and early/recycling endosomes. A small proportion of M-LumioGreen colocalized with LAMP-1 and Mannose-6-Phosphate receptor (Fig. 2-7A and B),
however the bulk of colocalization was with transferrin-TR (Fig. 2-7C). At higher
magnification, we showed the M-Lumio-Green distribution within the endosome was
asymmetric (Fig. 2-7D, arrows). In contrast, we observed a uniform distribution for noninfectious internalized ΔG-rVSV-M-Lumio-Green virions suggesting the asymmetric
distribution seen after entry of rVSV-M-Lumio-Green was G-dependent and could be the
result of one of two conditions. A model for an increase in G protein binding with
endosomal membranes at low pH has previously been proposed (59) and could explain
the rVSV-M-Lumio-Green asymmetric distribution as virions that have not fused could
still be bound to the inner leaflet of the endosomal membrane whereas ΔG virions would
not be able to bind in this manner resulting in the difference between the two
distributions. In the other condition, the increased binding affinity of G at low pH could
result in fusion of virions to one side of the endosome and the place where fusion occurs
could be marked by the membrane bound M population that is now on the outside of the
endosomal membrane after RNPs are released and this could not be seen as ΔG virions
lack the ability to fuse with the endosomal membrane. Here we hypothesize that the viral
envelope associated M-Lumio-Green is on the cytosolic side of the endosomal membrane
of early endosomes, after fusion, at the site of fusion.
While there is a need for microtubules to traffic vesicles within the endocytic
pathway (74), it has been shown that VSV has the ability to fuse with early endosomes
and release its genome prior to Rab7 dependent trafficking (54, 189). The distribution
observed after fusion (Figs. 2-8 and 9) and the M and N separation (Fig. 2-10B) in the
presence of cytoskeletal inhibitors seem to support the hypothesis that fusion and release
from early endosomes is the main entry pathway. The change in N staining (Fig. 2-10A
and B) at t-120 in the presence of nocodazole and cycloheximide could be the result of
two conditions; (i) protein synthesis was not completely blocked or (ii) the uncoating of
genomes has increased the amount of N protein that is available for staining, since the
scanning parameters (detector and gain settings) and amount of antibody for each
condition were kept the same. We also observed some LAMP-1 and M-6-P-R
colocalization with virus in Figures 2-7A and B which showed VSV can reach later
points in the endocytic pathway such as the endosomal carrier vesicles/multivesicular
bodies further along the pathway where it has been reported to undergo a back fusion
event for entry (117).
The ability of M-Lumio-Green to localize to the nuclear envelope without fully
polymerized actin (Fig. 2-8, arrows bottom panel) or tubulin (Fig. 2-9, arrows bottom
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panel) was unexpected since the localization seen in the synchronized entry assays
occurred within 20 minutes of post warm-up (Fig. 2-5, arrows bottom panel) which
suggested trafficking would be involved, along with the fact that M has nuclear
localization signals (69). We conclude that after uncoating, M-Lumio-Green distributes
to the nuclear envelope without the full cytoskeletal network that is known to contribute
to transport within cells (183) and therefore may get there by diffusion, but we also have
not directly ruled out delivery of M to the nuclear envelope by vesicular trafficking. Also
it has been shown that RaeI binds to microtubules in mitotic spindle complexes (17, 215)
and M may bind this protein in the cytoplasm and enter the NPCs in this manner.
Here we considered delivery of M-Lumio-Green to the nuclear envelope (Fig. 29, bottom panel arrows), separation of M and N (Fig. 2-10B), and productive infection
(Fig. 2-10C) after microtubule dissociation as clear indicators that uncoating occurs at
early endosomes along the endocytic pathway. The distribution that we observed was
different from the completely cytosolic and nuclear distribution of M we expected after
uncoating (174). This difference could be attributed to the M labeling technique, lower
MOIs, and the confocal microscopy used for this study. Instead of visualizing uncoating
as M being distributed throughout the cytosol as expected, we have shown that this
process is visualized by asymmetric association of M with endosomes possibly at sites of
fusion and delivery of a fraction of M to the nuclear envelope. Use of rVSV with MLumio-Green and other viral proteins fused to red and yellow fluorescent proteins would
allow for a tri-fluorescent virus to study entry in greater detail giving us further insight
into the mechanisms of VSV uncoating.
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Chapter 3: Low pH Enhancement of Matrix Uncoating
Introduction
Vesicular stomatitis virus (VSV), a prototype enveloped, nonsegmented,
negative-strand RNA virus in the family Rhabdoviridae, is composed of an 11 Kb
genome that encodes five genes (3’-N-P-M-G-L-5’). These genes are the nucleocapsid
protein (N), the phosphoprotein (P), the matrix protein (M), the glycoprotein (G), and the
large RNA dependent RNA polymerase protein (L). The virion’s structure is composed
of a helical nucleocapsid, containing L-P-N-RNA-M, surrounded by a membrane derived
from an infected host cell membrane with transmembrane, trimeric G proteins protruding
from the surface. These bullet-shaped VSV particles are 180 nm long and 75 nm wide
with around 400 trimeric G protein spikes on the exterior of the viral membrane and
about 1,800 molecules of M protein between the nucleocapsid core and the viral
membrane (199). The RNA genome is encapsidated by N protein with around 1,200
molecules of this protein tightly complexed to the RNA like beads along a string (199).
The RNA-dependent RNA polymerase, consisting of the L and P proteins, is associated
with this ribonucleoprotein complex and these proteins are present at 50 and 500
molecules per virion, respectively (199). This L-P-N-RNA complex makes up the
ribonucleoprotein particle (RNP) which is coiled into a tightly packed helix of around 35
turns inside the viral membrane. The M protein condenses the RNP into this tightly
packed helix, which, when condensed as described, is referred to as the skeleton (153,
154). A population of membrane bound M anchors the skeletons to the viral membrane
(31, 151).
When VSV enters the host cell through the clathrin-mediated endocytic pathway
(139), it uses the decreasing pH of endocytic organelles as a trigger for fusion in order to
penetrate the cell as is the case for influenza virus (207). To enter the cell VSV virus
attaches to the surface and is endocytosed by coated vesicles and transported through the
endosomal pathway to early or late endosomes. In early endosomes, pH-dependent
fusion of the endosomal and viral membrane occurs and subsequent virus uncoating and
release of the genome in the form of the RNP (114, 136). The G protein of VSV is
directly responsible for entry steps attachment and fusion (18, 82, 134, 161, 198, 211)
where fusion results in the release of the RNP core into the cytoplasm where VSV
replication occurs (139). Either directly after or concomitant with membrane fusion, M
protein dissociates from the RNP core which results in the decondensation of the skeleton
(153, 154) and completes uncoating (174). After uncoating, the decondensed RNP serves
as a template for transcription of viral mRNAs by the packaged RNA-dependent RNA
polymerase.
Most enveloped virus particles entering a cell have highly condensed genomes
protected by proteins. Before these particles can replicate in a host cell, after fusion and
entry, uncoating is required and this is described as the dissociation of some proteins that
keep the genome in a condensed or a biologically inactive state. The interesting aspect of
uncoating is that this process is the opposite of what occurs to package the virus for
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release. Here lies the dilemma; how does the same protein of a virus accomplish two
distinct processes in the same intracellular environment. Viral uncoating, in the case of
VSV, is regarded as the dissociation of M from RNPs and is an essential step in entry
(130). Without the release of M protein transcription of viral mRNAs (productive
infection) cannot proceed since it has been shown that M protein inhibits transcription
(32, 44, 212). This essential step is also shared by influenza virus, another negativestrand RNA virus, which requires removal of its matrix protein (M1) for a productive
infection (102, 137). While in endosomes the M2 protein of influenza virus acts as an ion
channel (110, 169) that allows protons across the viral envelope (81). Acidification of
the virus interior decreases the interaction between M1 and nucleocapsids allowing for
their dissociation before entry of the nucleocapsids into the cytoplasm (222). VSV lacks
a similar proton channel, though previous studies have found that spike proteins of
enveloped viruses such as VSV, Sindbis virus, and Semliki Forest virus and Ebola virus
GP2 can increase membrane permeability (76, 101, 112). Though not studied in the
context of virus it has been suggested that the haemaglutinin (HA) protein of Influenza at
the pH required for fusion can also cause cell permeability and proton influx when found
on the cell membrane (182). As with influenza virus M1, VSV M protein is found within
the cytoplasm of the host cell in soluble form separated from nucleocapsids (174).
However, the regulatory elements involved in the dissociation of M protein from RNPs
are still not understood. In vitro studies using biophysical measurements at physiological
ionic strength (60-90mM NaCl) showed that the association of M with the RNP had the
characteristics of a dynamic reversible equilibrium (130). This suggested that M protein
will dissociate from skeletons in the cytoplasm of newly infected cells, and later in
infection the concentration of M is high enough for equilibrium to be reached with
regards to cytoplasmic and skeleton associated M (130). These in vitro observations
could explain why dissociation and association of M can occur under the same ionic
conditions, however little is known about the contribution of host factors in dissociation
and the distribution of M protein during uncoating.
To study the release of M protein during uncoating, we developed and
characterized a recombinant VSV (rVSV, (rVSV-M-Lumio-Green)) encoding an M
protein that could be fluorescently tagged and gave us the ability to follow the fate of
fluorescent M during entry of virions (Chapter 2). Here, we report that there is a transient
loss of fluorescence intensity of rVSV-M-Lumio-Green virions at early times after the
initiation of endocytosis in a synchronized entry assay. In vitro, rVSV-M-Lumio-Green
particles had strong fluorescence when excited at a wavelength of 508nm at pH 7, but
there was a dramatic loss in fluorescence when the pH was lowered. Based on the pHdependent fluorescence properties of LumioTM Green, this observation suggested that the
interior of the virion was becoming acidified. We found that the effect of pH on the MLumio-Green fluorescence within intact virus was G-dependent and further biochemical
analysis indicated that low pH resulted in an enhancement of M dissociation from
partially permeabilized but intact virions. We propose a model for the initial uncoating
events of VSV based on our observations and past viral spike protein membrane
disruption studies (76, 101, 112, 182).
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Materials and Methods
Viruses. rVSV-wt was used in biochemical analysis of 35S-Methionine labeled
virions. rVSV-M-Lumio-Green (Chapter 2) was used in live-cell synchronized entry
assays (in BHK-21 cells at MOI 50) and in the fluorometric assays. ΔG-rVSV-MLumio-Green pseudotyped with either G or G-stem (GS) with a N-terminal
haemaglutinin (HA) tag (GSHA) complemented ΔG-rVSV-M-Lumio-Green were also
used in the fluorometric assays. ΔG-rVSV-M-Lumio-Green were complemented with G
or GSHA by methods used in previous studies (93) with some modifications. Briefly,
BHK cells at ~80% confluency were transfected with 2 µg of pC-G or -GSHA plasmid and
infected with G-complemented ΔG-rVSV-M-Lumio-Green at MOI 10 at 18 hours post
transfection. The Lumio-tagged viruses were labeled as done previously (Chapter 2)
using 200nM LumioTM Green in Opti-MEM I at 4 hours post infection. Eighteen hpi the
viral supernatants were collected and ultracentrifuged over a 20% sucrose cushion at
38,000 rpm in an SW41 swinging bucket rotor (Beckman) to pellet the virions. The
supernatant and sucrose cushion were then removed by aspiration and the viral pellet was
resuspended on ice in 10% sucrose TN solution (10 mM Tris-HCl [pH 8.0], 150 mM
NaCl). Residual unbound LumioTM Green reagent was removed from the virus
preparation by passing 100 µl aliquots through Sephadex G-50 (Fine) columns (Roche)
by centrifugation according to the manufacturer’s instructions. The void volume was
then analyzed for the fluorescence intensity using a fluorometer (Perkin Elmer LS 50 B)
and protein composition was analyzed by Coomassie stained SDS-PAGE in which
equivalent fluorescence was loaded. Viral preparations were used immediately resulted
in disruption of the viral envelopes.
Live-cell synchronized entry assay. To examine entry of labeled virus into live
cells, ΔG or rVSV-M-Lumio-Green (MOI 50) together with 50 µg of transferrin-TR were
added to BHK-21 cells in 35 mm glass bottomed culture dishes (MatTek Corporation) at
90% confluency after cells had been washed twice with 2ml of ice-cold Opti-MEM I.
After the ice-cold wash, the plates were placed at 4oC for 10 minutes and (as done
previously Chapter 2). The virus and transferrin-TR were adsorbed for 90 minutes in 100
µl ice-cold Opti-MEM I with rocking every 15 minutes at 4oC. The cells were covered to
prevent light photobleaching. Five plates of cells were used per experiment, each
corresponding to a 5 minute time point post entry. After the 90 minute adsorption, 37oC
media was added to initiate entry. The binding of rVSV-M-Lumio-Green and transferrinTR at the non-entry time point (t-0) was observed by laser scanning confocal microscopy
(Zeiss LSM 510) following addition of 2 ml of ice-cold Opti-MEM I. Separate plates
were used to examine entry after addition of 37oC media 5, 10, 15, and 20 minutes (t-5, t10, t-15, t-20) by confocal microscopy. Pixel intensity of rVSV-M-Lumio-Green
fluorescence was analyzed using the Profile function of LSM software (version
3.2).within transferrin-TR containing endosomes and then plotted as mean pixel intensity
as a function of time. GraphPad software was used to calculate the P values by the twotailed t-test for the statistical analysis of the mean pixel intensity.
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Fluorometric assay. To measure the fluorescence intensity of rVSV-M-LumioGreen virions in vitro, we placed 1 µg of the virus in HMN (HEPES 10mM, MES 10mM,
NaCl 150mM, pH 7) buffer and measured the fluorescence signal over 10 seconds at 1
second intervals for each measurement with a Perkin Elmer LS 50B. To determine the
effect of pH on fluorescence intensity of, we recorded the fluorescence signal at pH 7 and
added 1M NaOH to raise the pH to 7.5 and then 8 taking readings at each point. We then
dropped the pH by adding 1M HCl to reach a pH of 6.5, 6, 5.5, or 5 with fluorescence
signal recorded for each pH. These readings were then quantified as a percentage of
fluorescence intensity loss from the pH 7 signal.
To determine if G was important for the decrease in fluorescence intensity signal
of rVSV-M-Lumio-Green virions, we applied the same protocol for the pH-dependent
fluorescence intensity measurements of ΔG-rVSV-M-Lumio-Green and GSHA
complemented ΔG-rVSV-M-Lumio-Green virions. These virions were normalized to the
same fluorescence signal for each experiment (since these are not infectious) and were
based on the ΔG-rVSV-M-Lumio-Green signal since this virus produces the lowest
amount of virus. Virions were then analyzed by SDS-PAGE based on their fluorescence
signal. To determine if the viral envelope was a barrier to the pH effect on M-LumioGreen signal, virions were solubilized HMN buffered to pH 5.5 with 0.1% Triton X-100
(w/v) after the initial readings at pH 5.5, and the percent fluorescence loss was measured
from pH 7 readings.
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S-methionine labeling of rVSV-wt. BHK-21 cells were infected with rVSVwt at MOI 5. At 4 hours post infection the cells were starved of methionine for 30
minutes and then 35S-methionine in methionine-free DMEM (50µCi/ml) was added to the
cells. Fourteen hours post infection the virus was isolated from the supernatant by
ultracentrifugation (27K rpm, Beckman SW-28) over a 20% sucrose TN cushion for 1.5
hours. The amount of protein in the viral preparation was determined using a BCA
protein assay (Pierce) following the manufacturer’s instructions.
Lysolecithin treatment of rVSV-wt. To test the effect of on internal VSV
proteins, we applied a method of gently “poking holes” in the viral envelope using the
mild detergent lysolecithin that has been used to permeabilize cells in other studies (6,
124). To determine the appropriate concentration to use, we treated 1 µg of 35Smethionine labeled rVSV-wt with varying concentrations of lysolecithin ranging from 0,
3.9, 7.8, 15.6, 31.2, and 62.4 µg/ml at pH 5.5 for 10 minutes on ice. The suspension was
ultracentrifuged for 35 minutes (45K rpm, Sorvall AH-650) over a 20% sucrose TN (10
mM Tris-HCl pH 8, NaCl 150mM) cushion to separate the proteins in the supernatant
from the virus that pelleted to the bottom of the tube. The supernatant was TCA
precipitated, resuspended in reducing sample buffer, and loaded onto SDSpolyacrylamide gels and compared to the whole pellet by fluorography.
To compare protein in the supernatant of virions treated with lysolecithin at pH 7
and pH 5.5, we treated 1 µg of 35S-methionine labeled rVSV-wt with lysolecithin at a
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concentration of 3.9 µg/ml in HMN buffer at pH 7 or pH 5.5. We prepared the mixes as
stated above and quantitated the amount of 35S-methionine labeled M protein in the
supernatant to the N protein in the pellet by phosphorimaging.
TEM of rVSV-wt treated with lysolecithin. To confirm virions were not
disrupted by lysolecithin treatment 1 µg of rVSV-wt was treated with lysolecithin (3.9
μg/ml) in HMN buffer at pH 7 or pH 5.5 and ultracentrifuged over a 20% sucrose
cushion. The pellets were resuspended in 10% sucrose and placed on ice. To decrease
the sucrose concentration, the virus preparations were then diluted 1:10 in dH2O and
prepared for transmission electron microscopy (TEM) by adsorbing virus to a grid using
the drop-to-drop method and negative staining with 2% phosphotungstic acid (PTA, pH
5.9).

Results
Loss of fluorescence intensity over time during rVSV entry. To follow the
entry of ΔG (bald) or rVSV-M-Lumio-Green (G containing) virions into live cells, we
adsorbed virus (MOI 50) onto cells at 4oC to synchronize their entry as described in
Chapter 2 for figure 2-5. We used transferrin conjugated to Texas Red (transferrin-TR)
as an endosomal marker during endocytosis of the virions and the cells were observed
using confocal microscopy every 5 minutes over a 20 minute span, post addition of media
at 37oC. Single images from parallel sets of plates were collected at identical detector
and gain settings for each time point, and in which the threshold value was set to ensure
no pixel saturation occurred. By keeping the settings the same, and below threshold, we
quantified the average fluorescence intensity from multiple cells between time points.
We observed that the fluorescence intensity of rVSV-M-Lumio-Green virions decreased
over the time course of entry (Fig. 3-1A, left-hand graph). These data (n=50 per time
point in triplicate) were compiled using the Profile function of the LSM 510 software
(Zeiss version 3.2), which measures peak intensity and size of fluorescent signals for
each scan. The size of the particles within endosomes from which the fluorescent
intensity measurements were collected were no larger than 180nm, which is similar to the
average length of a VSV virion (VSV’s size is ~180nm x 70nm). Only M-Lumio-Green
signals that colocalized with transferrin-TR were used for quantification which ensured
the fluorescence intensity measured was within an endosome. We observed the largest
reduction in fluorescence intensity of rVSV-M-Lumio-Green particles at 15 minutes post
addition of warm media, where the mean fluorescence intensity was 27% below that of t0. This difference was statistically significant with a P value less than 0.0001 using a
paired t-test for the mean intensity of particles (Fig. 3-1A, right-hand graph). Also, when
we compared the mean fluorescence intensity of ΔG and rVSV-M-Lumio-Green particles
at t-15 (Fig. 3-1B) the difference was found to be 27.3% which was also statistically
significant (p < 0.0001).
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Figure 3-1. ΔG and rVSV-M-Lumio-Green fluorescence intensity during entry.
(A) From synchronized entry assay images in Chapter 2 (Fig. 2-5). rVSV-M-LumioGreen virions and transferrin-TR were bound to BHK-21 cells in cold media for 90
minutes, then the cells were washed and warm media was added to allow entry to occur.
The fluorescence intensity of M-Lumio-Green particles, with transferrin-TR positive
endosomes that measured ~180nm using the Zeiss LSM 50 profile software was read for
50 particles per time point in triplicate every 5 minutes for 20 minutes (left-hand graph).
The difference in average fluorescence intensity at 0 minutes and 15 minutes post warm
media addition was significant. (*, right-hand graph) p < 0.0001 using a paired t-test.
(B) Comparison of the average fluorescence intensity of bald ΔG and rVSV-M-LumioGreen virions 15 minutes post warm media addition. (*) p < 0.0001 using a paired t-test.
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Loss of fluorescence intensity of rVSV-M-Lumio-Green in the presence of
low pH. In the live-cell entry assay we observed a difference in mean fluorescence
intensity of particles when bound to the cell surface at t-0 and at t-15 where most of the
endocytosed virus would be in endosomes at the appropriate pH for fusion of the viral
envelope and endosomal membrane (51, 58, 172) (Fig. 3-1A). This observation was
interesting when one considers that the apparent pKa of LumioTM Green for the
tetracysteine motif is 5.4 (70). We reasoned that acid pH could be responsible for the
decrease in fluorescence intensity during entry since VSV enters the cell through the
clathrin-mediated endosomal pathway where the lumenal pH of endosomes drops as they
move from early to late endosomes. To assess whether pH had an effect on the
fluorescence of rVSV-M-Lumio-Green virions, we mimicked the drop in pH along the
endosomal pathway by addition of HCl to a HMN (HEPES 10mM, MES 10mM, NaCl
120mM) buffer and measured (in triplicate; standard deviations shown) the effect on
rVSV-M-Lumio-Green fluorescence in vitro using a fluorometer. When excited at a
wavelength of 508nm in HMN buffer at pH 7, 1 µg of rVSV-M-Lumio-Green virions
gave an average fluorescence reading of 34.5 (+/- 4.7) at 528nm, when excited at a
wavelength of 508nm. The fluorescence was similar at a pH of 7.5 and 8.0; however, we
found that below pH 7 the fluorescence of rVSV-M-Lumio-Green progressively
decreased as the buffer became more acidic (Fig. 3-2A). These data confirmed that loss
of LumioTM Green fluorescence intensity was pH-dependent. Interestingly, at a pH of 6,
the pH at which G-mediated fusion occurs, we observed a similar loss of fluorescence
intensity in vitro as was seen at t-15 in cells (29% versus 27%, respectively). We also
observed that the curve for fluorescence intensity loss was similar to pH curves seen for
VSV G protein-dependent fusion (51, 172). This similarity suggested that G somehow
contributes to the loss in fluorescence, which we interpret as exposure of M-LumioGreen to acidic pH within the intact virions.
Fluorescence intensity loss of rVSV-M-Lumio-Green is G protein dependent.
To determine if G was involved in the fluorescence intensity loss, we compared the
responses of rVSV-M-Lumio-Green and ΔG-rVSV-M-Lumio-Green virions to low pH.
To determine if there was a difference in the incorporation of LumioTM Green into ΔG
virus compared to virus containing G protein we evaluated the protein to fluorescence
ratio by Coomassie stained SDS-PAGE gels. We observed that there was a similar
amount of VSV proteins when normalized by fluorescence signal (Fig. 3-2B). We then
tested whether ΔG-rVSV-M-Lumio-Green virions would lose fluorescence in a manner
like rVSV-M-Lumio-Green when exposed to low pH. We measured the initial
fluorescence of virions in HMN buffer at pH 7 and added HCl to bring the pH to 5.5 (in
triplicate) and measured fluorescence intensity again. The fluorescence signal of the G
containing virus was reduced 57% while bald ΔG virus lost only 8% (Fig. 3-2C, lefthand bars). To determine if removal the envelope of the ΔG-rVSV-M-Lumio-Green
virions could result in the loss in fluorescence, we added detergent to the virion preps
(both G containing and bald) to solubilize the envelopes and found that there was a loss
in fluorescence intensity similar to rVSV-M-Lumio-Green virions (Fig. 3-2C, right-hand
bars).
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Figure 3-2. pH- and G-dependence of fluorescence intensity loss.
(A) Percentage of fluorescence intensity loss over a pH range from 8 to 5.5 when
compared to fluorescence at pH 7. rVSV-M-Lumio-Green virions were suspended in
HMN buffered to the indicated pH and the fluorescence was read by a fluorometer in
triplicate. Standard deviations are shown. (B) Representative Coomassie stained SDSPAGE of rVSV-M-Lumio-Green and ΔG-rVSV-M-Lumio-Green virions. The amount of
virus loaded was based on the fluorescence signal and 35 fluorescence units were
examined. (C) Fluorescence intensity loss for rVSV-M-Lumio-Green and ΔG-rVSV-MLumio-Green virions at pH 5.5 plus or minus detergent when compared to fluorescence at
pH 7. Samples were measured in triplicate and standard deviations are shown.
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It was previously reported that VSV released from cells expressing G on their
surface could incorporate a truncated version of G made up of 71 amino acids that
contained the transmembrane domain and cytoplasmic tail (29). It was also shown that
ΔG-rVSV could incorporate a version of this protein that has the full cytoplasmic tail of
G, the transmembrane domain, and the 42 membrane-proximal amino acids on the
exterior of the envelope which was named G-stem (GS) (176). Considering this protein
can be found in virions that express the full-length G protein (29), we wanted to assess
whether or not GS could be involved in fluorescence intensity loss observed at low pH
for rVSV-M-Lumio-Green virions. Virus containing GS and M-Lumio-Green was
produced by complementing ΔG-rVSV-M-Lumio-Green virions with GSHA (N-terminal
haemaglutinin (HA) tag on GS; (94)). We also generated virus complemented with wildtype G (wt-G) to ensure similar virus preparations were compared. The amount of GSHA
incorporated into the complemented virus was similar to that found in virus pseudo-typed
with wt-G as determined by immunoblot analysis using a monoclonal antibody to the
cytoplasmic tail of G on an immunoblot (Fig. 3-3A). Equivalent amounts of the two
viruses based on fluorescent signal were treated at pH 5.5 and the reduction in
fluorescence intensity from pH 7 was compared. We observed a larger loss of
fluorescence signal with the GSHA complemented virions versus ΔG-rVSV-M-LumioGreen virions; however the reduction was not as much as the virus with the full-length G
protein (Fig. 3-3B).
Low pH enhances release of M protein from VSV virions. To determine if the
loss in fluorescence observed when rVSV-M-Lumio-Green is exposed to low pH
represents a biologically relevant acidification of the virion interior we asked whether
internal viral proteins were affected when virus was suspended in low pH buffer. We
hypothesized that low pH may be important for virus uncoating as had been shown for
influenza virus (222), therefore we gently “poked holes” in the viral envelope using
lysolecithin (6, 124), in the presence of low pH to allow any pH affected proteins on the
inside of the virion to be released into the supernatant. To establish the conditions
necessary to permeabilize virions without solubilizing the viral envelope, we labeled
rVSV-wt virions with 35S-methionine and treated them at pH 5.5 in HMN buffer with
different concentrations of lysolecithin and pelleted the mixture over a sucrose cushion
where the released proteins would be in the supernatant and retained proteins in the viral
pellet (Fig 3-4A). With the loss of G protein in lower lysolecithin concentration
treatment we established appropriate conditions for our analysis (Fig. 3-4A). We also
confirmed that the lysolecithin (3.9 µg/ml) treated virions at pH 7 or pH 5.5 were intact
by negative stain transmission electron microscopy (TEM) (Fig 3-4B), indicating that we
were observing the release of M from the virions rather than from disrupted RNPs. When
virions were treated with either 3.9 or 7.8 µg/ml lysolecithin at pH 5.5 some of the M
protein was released and remained in the supernatant.
To determine if there was a difference in the amount of M released into the
supernatant at pH 7 versus pH 5.5, we treated 1 µg of virions with or without lysolecithin
in HMN buffer at pH 7 or pH 5.5 for 10 minutes on ice and then ultracentrifuged the
mixtures over a sucrose cushion to separate any released protein in the supernatant from
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Figure 3-3. Effect of GSHA on fluorescence intensity loss.
(A) Immunoblot using monoclonal antibody to the cytoplasmic tail of the G protein to
assess relative levels of G and GSHA incorporation into ΔG-rVSV-M-Lumio-Green
virions. The amount of virus loaded for each sample was based on the fluorescence
signal and 35 units of fluorescence were examined. (B) Fluorescence intensity loss for G
and GSHA complemented ΔG-rVSV-M-Lumio-Green virions at pH 5.5 when compared to
pH 7 fluorometer readings in triplicate and standard deviations are shown
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Figure 3-4. Lysolecithin treatment of rVSV-wt.
(A) Fluorograph of 35S-methionine labeled rVSV-wt treated with different lysolecithin
concentrations in HMN buffer at pH 5.5. The mixtures were ultracentrifuged over a
sucrose cushion and the pellet and TCA precipitated supernatant were run on an SDSPAGE gel. (B) Transmission electron microscopy of rVSV-wt in HMN buffer at pH 7 or
pH 5.5 treated with lysolecithin at a concentration of 3.9 µg/ml. 100,000x Bar equals
150nm.

55

protein retained in the virions. There was no protein release when virus was in the
absence of lysolecithin at either pH; however, we observed a difference in the amount of
M released from lysolecithin permeabilized virus in HMN buffer at pH 7 and pH 5.5
(Fig. 3-5A). Quantification of the amount of M released as determined by the ratio of
M/N for virions treated with lysolecithin was 15% (+/- 1 SD) at pH 7 and 28% (+/- 2 SD)
at pH 5.5 (Fig. 3-5B). Therefore, low pH enhanced the release of M protein from virions,
but was not absolutely required.

Discussion
Directly after or concomitant with viral membrane fusion to the endosomal
membrane, VSV M protein dissociates from the RNP core which results in the
decondensation of the skeleton (153, 154) and the RNP is released into the host
cytoplasm thereby completing uncoating (174). After uncoating, the decondensed RNP
serves as a template for transcription of viral mRNAs by the packaged RNA-dependent
RNA polymerase. This uncoating process is the opposite of what occurs when virus is
assembled from infected cells. The exact mechanisms by which VSV can accomplish the
two distinct events for the same protein are not fully understood. Uncoating of another
enveloped negative-strand RNA virus, influenza virus, requires removal of its matrix
protein (M1) for a productive infection (102, 137). The mechanism for uncoating of
influenza virus has been shown to be influenced by pH with the M2 protein of influenza
virus acting as an ion channel (110, 169) that allows protons across the viral envelope
(81). Acidification of the virion interior decreases the interaction between M1 and
nucleocapsids allowing for their dissociation before entry of the nucleocapsids into the
cytoplasm (222). To understand the uncoating mechanism of VSV, we developed and
characterized the virus rVSV-M-Lumio-Green which gave us the ability to follow
fluorescent M release and distribution during entry of virions in live-cell studies (Chapter
2). rVSV-M-Lumio-Green virions were constructed with an M protein that has a Cterminal fusion to a tetracysteine (-CCRECC-) LumioTM tag. This allowed the
fluorescent labeling of M with the biarsenic fluorescein reagent LumioTM Green (2, 64,
70).
During live-cell synchronized entry assays we observed a loss in fluorescence
intensity of rVSV-M-Lumio-Green virions during endocytosis of virus after the addition
of warm media. The reduction in fluorescence signal peaked at 15 minutes post warm
media addition (Fig 3-1) and then steadily increased thereafter. When we considered the
pKa of the interaction between the fluorophore and the tetracysteine motif (70), the data
suggested that the acidic environment of endosomes at t-15, where most of the
endosomes would be near the appropriate pH for fusion of the viral envelope and
endosomal membrane (51, 58, 172), had an effect on the fluorescence of rVSV-MLumio-Green (Fig. 3-1B). Indeed, we observed an effect on fluorescence intensity when
the pH was reduced from 7.0 to 5.5. In fact, the percentage of fluorescence loss seen
within cells at t-15 (Fig. 3-1A, right-hand graph) was similar to the loss at pH 6 in vitro
(Fig. 3-2A). By 15 minutes the virus has likely reached an endocytic compartment with a
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Figure 3-5. Lysolecithin treatment of rVSV-wt at pH 7 and pH 5.5.
(A) Representative fluorographs of 35S-methionine labeled rVSV-wt treated at a
concentration of 0 or 3.9 µg/ml lysolecithin concentrations in HMN buffer at pH 7 or pH
5.5. (B) Quantification of M protein release as determined by the percentage of M in the
supernatant when compared to the amount of N found in the pellet. Data are the mean
and standard deviation for the experiment performed in triplicate.
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pH close to 6.0 (75). We also observed that the curve for fluorescence intensity loss was
similar to pH curves for VSV G protein pH-dependent fusion (51, 172) further suggesting
a correlation between pH-dependent conformation changes in G and the effect resulting
in changes in M-Lumio-Green fluorescence. We then compared the fluorescence
intensity loss of ΔG-rVSV-M-Lumio-Green and virions complemented with G (Fig. 32C) and GSHA (Fig. 3-3) in the presence of low pH and found that the full-length G
protein was needed for the maximal effect of pH on fluorescence in vitro.
When we considered the pKa of LumioTM Green when bound to the tetracysteine
motif and compared the loss of fluorescence between G, and ΔG virions either treated or
not treated with detergent (Fig. 3-2B), we concluded that G in the presence of acidic pH
was responsible for acidification of the interior of rVSV-M-Lumio-Green virions. This
was an interesting result since influenza virus uses the M2 ion channel protein for
acidification of the virion interior (110, 169) and our results suggested that VSV uses a
different method to accomplish a similar feat with its G protein. Previous studies have
found spike proteins of several different enveloped viruses including VSV, Sindbis Virus
(SIN), Semliki Forest virus (SFV), influenza HA, and Ebola virus GP2 when exposed to
acidic pH, can increase membrane permeability when cells expressing these proteins on
the cell surface are exposed to low pH (76, 101, 112, 182). The SFV spike protein’s
involvement in membrane disruption at low pH was extensively studied with cell
permeabilization assays, whole-cell patch-clamp recordings, and dual voltage-clamp
intracellular current flow monitoring (112, 113, 115) and was predicted to be due to pore
formation by the E1-E2-E3 protein trimers that make up the SFV spike (114). However,
the mechanism of how G protein may permeabilize the VSV envelope has yet to be
investigated. The G protein may form a pore while under going pH-dependent
conformational changes (161, 177, 178) or rearrangement of G protein trimers to the
virion poles (22) may cause enough disruption of the envelope to allow protons to the
interior of the virion.
The influenza virus M1 protein is affected by low pH within the virion which has
been shown to decrease the interaction between M1 and nucleocapsids resulting in their
dissociation before entry of the nucleocapsids into the cytoplasm (222). It has also been
proposed that the capsid protein of SFV is affected by pH in a similar manner that would
allow for efficient uncoating and association of its genome with ribosomes (114). After
our observation that pH affected the fluorescence intensity of M-Lumio-Green within
virions in a G protein and pH-dependent manner (Fig. 3-2), we reasoned that exposure to
low pH may affect the M proteins within VSV virions in a similar manner. It was
previously shown that M protein exists in a dynamic equilibrium in its association with
nucleocapsids and that low pH did not have an effect on this equilibrium (130).
Consistent with the results of that study, we found that skeletons treated with pH 5.5-6.0
did not release M protein from RNPs (data not shown). Even though these results
suggested that pH has no effect on the association of the population of tightly bound M
associated with RNPs, we reasoned that low pH may affect a different population of M
inside the virion, in particular the M associated with the viral envelope that acts as a
bridge to the nucleocapsid (31, 120, 221) versus the M associated with the nucleocapsid
after isolation from solubilized virions (10, 100, 153). Indeed, virions treated with
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lysolecithin in the presence of low pH showed an enhanced release of M protein when
compared to virions treated at neutral pH (Fig. 3-5). It is important to note that low pH
may not be absolutely necessary for uncoating to occur since VSV pseudotypes having
envelope that are pH-independent and that fuse at the cell surface are still infectious (95,
142, 159).
From this study we propose that when virions are exposed to the low pH
environment in the endosome during entry, the contact between the M that bridges the
viral envelope and the skeletons is reduced (30) (Fig. 3-6, green circles and black rimmed
circles respectively). Acidification may trigger a slight structural change in M that
reduces the interaction between M proteins and between the M and RNPs within the
virion just before or concomitant with fusion. This reduced contact between the M
populations would enhance the release of the skeleton into the cytosol. The M on the
released skeleton could then dissociate away from the RNP into the M protein-less
cytoplasm of newly infected cells as previously suggested (130). In summary we report a
low pH effect on M-Lumio-Green fluorescence within virions and a low pH enhancement
of M released from lysolecithin treated virions that together suggests pH is one of the
regulatory elements involved in VSV uncoating. Although this effect is accomplished by
a different mechanism in regards to influenza virus, it may indicate the involvement of
low pH as a trigger for uncoating for many enveloped viruses that enter the host cell
through the endocytic pathway.
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Figure 3-6. pH effect model.
(A) Illustration of pH effect on rVSV-M-Lumio-Green fluorescence and depiction of
what may occur to rVSV-wt when treated with lysolecithin. (B). Model for VSV
uncoating enhanced by endosomal pH. Acidification of the interior of virions in early
endosomes affects the contact between the RNP and membrane bound M proteins
(depicted by red stars) which results in the release of skeletons from membrane bound M
protein. The release of skeletons could occur in either way or both ways depicted and
then uncoating can be completed in the cytosol.
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Chapter 4: Examination of Mutations in the Exposed Loop of
the VSV Matrix Protein
Introduction
Vesicular stomatitis virus (VSV) is a simple, enveloped, non-segmented negativestrand RNA virus that has served as a model to study virus assembly. The matrix protein
(M) of VSV plays a key role in virus assembly by condensing the RNA genome and
influencing the budding of virions from host cells (30, 78, 91, 153). The M protein is
also involved in the cytopathic effects inflicted on host cells which include disruption of
cytoskeletal organization, inhibition of host mRNA expression, translation, and
nucleocytoplasmic transport (3, 4, 33, 53, 168).
Biochemical studies have suggested that an exposed protease-sensitive loop (120PAVLADQGQP-129) in M may be important for assembly of virions. Cleavage of the
loop with the protease thermolysin resulted in a matrix protein that no longer selfassociated (65, 66). M self-association has been implicated in condensation of the
genome (67, 154) which is thought to result in inhibition of viral mRNA synthesis (163)
and to be critical in assembly of bullet shaped virions (65-67, 153). Recently M loop
mutations at amino acids 121 to 124 were examined to assess their effect on assembly of
virions. The assembly effect observed was minor whereas these mutations resulted in a
reduction of viral protein synthesis (35). To address the involvement of the loop in virion
assembly, before the report on residues 121 to 124, we made different mutations within
the loop with the hypothesis that the amino acids present (aspartate residue 125 in
particular) were important for assembly. The mutants were studied in the context of M
protein activity, and by recovery and characterization of recombinant VSV (rVSV).
Cellular distribution and budding activity of the loop mutants were comparable to
wild-type. However, characterization of the mutant rVSVs revealed a reduction in
growth kinetics and viral budding activity, unlike previous rVSVs with different loop
mutations in M (35). Our results were consistent with the notion of that the loop may be
involved in assembly. In addition, 35S-methionine metabolic labeling studies revealed a
reduction in viral protein synthesis for the rVSVs containing loop mutations from 4 to 8
hours post infection, as reported by others previously (35). Real-Time RT-PCR of cells
infected with loop mutants revealed there was more viral mRNA in mutant infected cells
compared to wild-type infection. A broad analysis of host responses to viral products
that affect protein translation revealed that PKR activation, RNase L rRNA degradation,
IFN response, apoptosis or autophagy were not involved in the reduced protein synthesis.
We were able to show that this effect was most likely on a cap-dependent translation
factor as translation from a Type 2 internal ribosome entry site (IRES) was not affected.
These results suggest that the exposed protease-sensitive loop in M may be involved in
assembly and in viral translation or that the assembly defect causes a novel host response
to RNA virus infection.
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Materials and Methods
Plasmid design and construction. Construction of the cDNAs containing the
loop mutations in M was accomplished using pBluescript(BS) M-Lumio (Chapter 2) as a
vector and overlapping PCR to insert the mutations. Overlapping primers (CEM 9 and
10, 11, 12 and 13, 14 and 15, 16 and 17, 18 and 19, 20 and 21, 22 and 23, used in that
order for the mutations Δ Loop, 2X Loop, A Loop, D Loop, D125A, D125E, L123A, and
L123S respectively) which encoded the mutations were used for PCR amplification with
a 5’ forward primer (CEM 1) and a 3’ reverse primer (T3) respectively. Another round
of PCR amplification with the overlapping 5’ and 3’ fragments as the template and the
two outside (CEM 1 and T-3-reverse) were used to create the desired mutations in the MLumio gene. The PCR product was gel purified, digested with AscI and EagI, gel
purified, and ligated into pBS-SK-ΦT cut with the same enzymes.
Generation of full-length VSV cDNAs encoding M loop mutants. Creation of
the full-length VSV genomes with M loop mutants was accomplished by separately
cloning each sequence into a pΔM-PLF VSV anti-genome which has a multiple cloning
site in the place of the M protein coding sequence (91), except GFP is not encoded in the
plasmid. For each construct the plasmids were digested with AscI and EagI, the ΔM
vector and M loop mutant fragments were gel purified and ligated by two way ligation to
create pVSV-(Loop Mutation).
Recovery and characterization of recombinant VSV (rVSV). Recombinant
viruses were recovered using reverse genetics (116) with some modifications as
described previously (91). Single-step growth curves were performed by adsorbing virus
to baby hamster kidney (BHK-21) cells in 35 mm plates at a multiplicity of infection
(MOI) of 10 for 1 hour at 31oC while continually rocking. The inoculum was removed,
the cells were washed 4x with serum-free Dulbecco’s minimal Eagle’s medium (DMEM)
to remove unbound virus, DMEM containing 5% fetal bovine serum (FBS) was added,
and the cells were placed at 37oC. Every two hours post infection (hpi) a 5% aliquot of
media was collected, replaced with the same volume of fresh media, and then virus titers
were determined in duplicate by plaque assay on BHK-21 cells. Growth curves were
performed in triplicate for each virus. Relative infectivity was assessed by Coomassieblue staining after SDS-PAGE analysis of 1 x 107 PFU of rVSV.
TEM of rVSV. To confirm the morphology of rVSV, purified virus was
resuspended in 10% sucrose 10 mM Tris-HCl [pH 8.0], 150 mM NaCl solution and
placed on ice. To decrease the sucrose concentration, the virus preparations were then
diluted 1:10 in dH2O and prepared for transmission electron microscopy (TEM) by
adsorbing virus to a carbon-coated grid using the drop-to-drop method and negative
staining with 2% phosphotungstic acid (PTA, pH 5.9).
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Transient expression of M loop mutants. BHK-21 cells at ~90% confluency on
glass cover slips, were infected with a modified vaccinia virus (vTF7-3) encoding T7
RNA polymerase (61) at MOI 5 for 1 hour at 31oC in SF-DMEM. The inoculum was
removed and the cells were transfected with 5µg of pBS-MΦT (wild-type; Indiana) or
pBS-(Loop Mutant) using 20 µl TransfectACE in SF-DMEM (180). Five hours post
transfection (p.t.) the transfection mix was removed and replaced with 5% FBS DMEM
containing antibiotics (100U/ml streptomycin and penicillin), and 18 hours p.t. the cells
were fixed and processed for immunofluorescence or were used in a budding assay as
described below.
Immunofluorescence (IF) staining and confocal microscopy. Cells either
transiently expressing M proteins from plasmids or infected with rVSV were washed
twice with phosphate-buffered saline (PBS) and then fixed for 15 minutes with 3%
paraformaldehyde (PFA) in PBS at room temperature (r.t.). The fix solution was then
removed and the cells washed twice with PBS containing 10 mM Glycine and 0.05%
sodium azide (PBS-Glycine), and then permeabilized with 1% Triton X-100 in PBSglycine at r.t. for 1 minute. After permeabilization, the cells were washed twice with
PBS-Glycine and then stained for; M protein using an anti-M monoclonal antibody (mAb
23H12) conjugated to FITC or rhodamine, VSV N protein using anti-N mAb 10G4
conjugated to rhodamine., or microtubules using anti-α tubulin mAb (# A-11126,
Molecular Probes). The unconjugated primary antibodies were detected with a goat antimouse secondary antibody conjugated to rhodamine (Jackson Research Laboratories).
Phalloidin conjugated to Texas Red-X (Invitrogen; Molecular Probes) was used to stain
actin. The distribution of the indicated proteins was examined using laser scanning
confocal microscopy (Zeiss LSM 510). Optical slices of 1 µm were captured using
488nm or 543nm laser excitation.
Budding assays. Cells transiently expressing the indicated M protein were
washed twice with methionine-free, SF-DMEM and then incubated in this media for 15
minutes to deplete the intracellular methionine pools at 5 hours p.t. After depletion, a
media composed of 1 part 5% FBS DMEM to 9 parts methionine-free media and
supplemented with 50 µCi of 35S-Methionine (Met) Express Protein Labeling Mix
(Perkin-Elmer) per ml was added and 18 hours later media and cells were collected
separately and processed for immunoprecipitation (IP).
The media were centrifuged at 170 x g for 10 minutes to remove dislodged cells
and the supernatant was placed on ice after addition of 200U of aprotonin (U.S.
Biochemicals). The supernatant was made to 50mM Tris-HCl, 150mM NaCl, 0.1% NP40, 1mM EDTA, 20mM NaN3, 0.3% SDS, and radio labeled M proteins were
immunoprecipitated with M mAb (23H12) overnight at 40C.
Cell extracts were prepared by washing the cells twice with PBS and then lysing
with 800 µl of detergent solution (10 mM Tris-HCl [pH 7.4], 66 mM EDTA, 0.4%
sodium deoxycholate, 1% Triton X-100, 0.05% NaN3) containing 200U/ml of aprotonin
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for 5 minutes at r.t. on a rocker. The cell extract was collected, nuclei and insoluble
material removed by centrifugation at 10,000 x g for 5 minutes and a 200 µl aliquot of
the cell extract was made to 0.3% SDS and immunoprecipitated with M mAb (23H12)
overnight at 4oC. One-quarter of the radio labeled M proteins in the cell extract were
compared to the amount released into the supernatant by SDS polyacrylamide gel
electrophoresis (PAGE) on a 9% polyacrylamide gel and visualized by fluorography.
Immunoblot analysis. To detect the proteins in BHK-21 or HeLa cells that were
mock treated/infected, rapamycin treated, or infected with rVSV cell lysates from ~ 106
cells were collected at different times post infection by addition 400 µl of detergent
solution (10 mM Tris-HCl [pH 7.4], 66 mM EDTA, 0.4% sodium deoxycholate, 1%
Triton X-100, 0.05% NaN3) containing 200U/ml of aprotonin. The cell extracts (5%)
were separated by SDS-PAGE on a 10% polyacrylamide gel and then transferred to a
polyvinylidene fluoride (PVDF) microporous membrane (Immobilon-P; Millipore).
Monoclonal antibodies to M (23H12), α tubulin (# A-11126, Molecular Probes), eIF2α (#
9722, Cell Signaling Technologies (CST)), phosphorylated eIF2α (# 9721, CST), caspase
3 (# 9668, CST), phosphorylated eIF4G (# 2441, CST), and LC3B (# 2775, CST) were
used to detect each protein followed by addition of a goat anti-mouse or -rabbit antibody
tagged with horseradish peroxidase (Jackson Research Laboratories). Proteins were
visualized using a chemiluminescence kit (Immobilon Western; Millipore) according to
the manufacturer’s instructions.
35

S-methionine pulse labeling of rVSV infected cells. BHK-21 cells were
infected with rVSV at an MOI of 10. At increasing times post infection the cells were
starved of methionine for 10 minutes and then an 35S-methionine labeling mix at
50µCi/ml was added to the cells for 10 minutes. Cell extracts were prepared by washing
the cells twice with PBS and then lysing with 400 µl of detergent solution (10 mM TrisHCl [pH 7.4], 66 mM EDTA, 0.4% sodium deoxycholate, 1% Triton X-100, 0.05%
NaN3) containing 200U/ml of aprotonin for 5 minutes at r.t. on a rocker. The nuclei and
insoluble material were removed by centrifugation at 10,000 x g for 5 minutes and 5% of
the cell extract was analyzed by SDS-PAGE fluorography and quantified by
phosphorimaging using a STORM (Molecular Dynamics) scanner.
rVSV budding assay. BHK-21 cells were infected with rVSV at an MOI of 10.
At 3 hpi, cells were starved of methionine for 10 minutes and then an 35S-methionine
labeling mix at 50µCi/ml was added to the cells for 1 hour. The supernatant was then
collected and virus was isolated from the supernatant by ultracentrifugation (35 minutes,
45K rpm, Sorvall, AH-650) over a 20% sucrose TN (10 mM Tris-HCl [pH 8.0], 150 mM
NaCl) cushion. Also, cell extracts were prepared by washing the cells twice with PBS
and then lysing with 400 µl of detergent solution (10 mM Tris-HCl [pH 7.4], 66 mM
EDTA, 0.4% sodium deoxycholate, 1% Triton X-100, 0.05% NaN3) containing 200U/ml
of aprotonin for 5 minutes at r.t. on a rocker. The nuclei and insoluble material were
removed by centrifugation at 10,000 x g for 5 minutes. The whole viral pellet and 5% of

66

the cell extract were analyzed by SDS-PAGE fluorography and quantified by
phosphorimaging using a STORM scanner.
Synchronized fusion co-infection assay. To prevent the acidification of
endosomes and synchronize fusion of virions with endosomal membranes we used the
lysosomotropic reagent NH4Cl as described previously (174) with some modifications.
BHK-21 cells were washed twice with PBS and then washed twice with PBS containing
100mM NH4Cl. rVSV (MOI 1), rVSV-D125A (MOI 10), or rVSV-wt (MOI 1) and
rVSV-D125A (MOI 10) were adsorbed in SF-DMEM containing 100mM NH4Cl for 90
minutes. After adsorption the cells were washed with PBS four times to remove the
NH4Cl and protein synthesis or virus budding was examined by 35S-methionine pulse
labeling as described above.
RNP exchange assay. 35S-methionine labeled M-wt or M D125A mutant protein
was made from plasmids in a TNT T7 in vitro transcription and translation reaction (#
L4610, Promega) in the presence of 35S-methionine labeling mix (# AG1594, GE
Healthcare). Five microliters of either translation reaction was added to 10, 50, or 100 µg
of solubilized rVSV-wt or rVSV-D125A in TN (Tris-HCl (pH 8.0), 150mM NaCl)
buffer. The mixtures were placed on ice for 10 minutes and then the RNPs and
supernatants were separated by ultracentrifugation (35 minutes, 45K rpm, Sorvall, AH650) over a 20% sucrose TN cushion. Pellets and TCA precipitated supernatants were
then analyzed by SDS-PAGE fluorography.
RT-PCR analysis. To rule out viral mRNA as the limiting factor in the reduction
in protein synthesis during infection, real-time RT-PCR was performed on BHK-21 cells
infected with rVSV at an MOI of 10 and at increasing times post infection cell lysates
were collected in Trizol reagent (# 15596-018, Invitrogen) and total RNA was extracted.
Reverse transcription was performed using a primer (MR Nest) on a known amount of
genomes from 101 to 1013 to produce a standardized genomic curve for RT-PCR.
Reverse transcription was also performed on total RNA extracted from cells using a poly
dT primer for mRNA and a primer (MR Nest) that annealed to the intergenic region
between M and G for genomes. RT-PCR was then performed and RNA was quantified
using SYBR Green for genomes (primers CEM 2 and MR Nest) and P mRNA (P82F and
P-210-REV) in a DNA Engine Opticon system and software (MJ Research/BioRad).
Luciferase assays. HeLa cells were mock transfected, transfected with a nonreporter plasmid, or 125 ng of a plasmid that encoded Firefly luciferase under the control
of the IFNβ promoter (p IFNβ-Luc) that expressed luciferase. Five hours post
transfection of IFNβ-Luciferase plasmid cells were mock treated/infected, treated with
125U of human IFN, or infected with rVSV-wt or rVSV-D125A at an MOI of 10. Cell
lysates were collected at increasing times post infection and analyzed using a luciferase
assay system (# E1500, Promega) in a luminometer (Turner Designs, TD-20/20).
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HeLa cells were also transfected with 2 µg of a plasmid that expressed luciferase
from a chicken actin promoter (pCAAGs-Luc) and at 5 hours post transfection were
mock infected or infected with rVSV-wt or rVSV-D125A at an MOI of 10 and cell
lysates at increasing times post infection were analyzed for luciferase activity as
described above.
BSR cells (BHKs constitutively expressing T7 RNA polymerase, (179)) were
transfected with 5 µg of a plasmid that expressed luciferase with an internal ribosome
entry site (pEMCV/IRES-Luc) and 18 hours post transfection the cells were mock
infected/treated, treated with cycloheximide (10 µg/ml), or infected with rVSV-wt or
rVSV-D125A at an MOI of 10. Mock and cycloheximide treated cell lysates were
assessed for luciferase activity at 6 hours post treatment and luciferase activity was
measured at increasing times post infection in infected cells as described above.

Results
Recovery and characterization of recombinant (r)VSV with M loop
mutations. To investigate the role that the amino acids within the protease-sensitive loop
of M protein may play in virus assembly we constructed M proteins with mutations in the
loop (Fig. 4-1A). All of the constructs included a C-terminal Lumio tag, which we have
shown does not affect M protein localization, budding activity, or uncoating when
assembled into virus particles (Chapter 2). Figure 4-2A shows an alignment of the
putative loop regions of vesiculovirus M proteins showing that the aspartate residue
(highlighted) is also conserved. To determine if the loop in M had conserved sequences
we performed a PubMed blast search of the virus protein database and Figure 4-2B shows
the results that revealed an LXD sequence for other virus proteins. Based on these
alignments (Fig. 4-2), the mutations in Figure 4-1A were constructed to determine
whether the loop (Δ Loop), size of the loop (2X Loop), or specific amino acids were
involved in the assembly and/or uncoating of VSV.
To assess the cellular distribution and assembly function of these M proteins with
loop mutations, we transiently expressed these proteins in cells and compared them to Mwt by immunofluorescence microscopy (IF)) and in a budding assay (Figs.4-1B and C).
There were no discernable difference in the intracellular distributions of the M loop
mutants as they all were located in the nucleus, were cytosolic, and localized to the
plasma membrane as determined by reactivity with a monoclonal anti-M antibody
conjugated to rhodamine (Fig. 4-1B). The loop mutants also had wild-type budding
activity (Fig. 4-1C lane 6). Note D125A is the only mutant shown in the IF and budding
assay but the other loop mutations retained similar wild-type activity.
To determine if M loop mutants could support virus assembly we replaced the
Mwt gene with the loop mutants in the viral genome (Fig. 4-1A). Only the viruses with
single amino acid mutations (D125A, L123A, and L123S) were recovered. Although we
did not recover the D125E mutant from plasmids, it was obtained as a “revertant” from
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Figure 4-1. Design and characterization of the M loop mutant proteins.
(A) Schematic of mutations made in the protease-sensitive loop region of M and their
location within rVSV genomes. The residues in grey color and underlined are either
mutated to the amino acids shown, or are added (2X Loop). The -PP- indicates deletion
of the loop region (Δ Loop) between the two prolines at residues 121 and 129 in the wildtype sequence (Mwt). All constructs contained a tetracysteine LumioTM tag. (B)
Transient expression of Mwt and the D125A loop mutant in BHK-21 cells stained using
an anti-M monoclonal antibody conjugated to rhodamine and examined by LSM using a
100X magnification objective and 543nm excitation. Image is a 1 µm optical section
through the middle of the cell. (C) Budding assay showing intracellular protein
expression (odd numbered lanes) and budding activity in mock transfected (lane 2), Mwt
(lane 4), and D125A (lane 6) transfected cells.
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Figure 4-2. M loop sequence alignments.
(A) Zoomed in view of predicted loops from matrix proteins of different Vesiculoviruses
showing the Leucine/Isoleucine and aspartate (L/I and D respectively, highlighted)
residue and their location in the sequences. Alignment of matrix proteins from Gaudier
et al. (66) using Clustal W was used to align the predicted loops. (B) Alignments and
results of a PubMed blast search for the VSV M loop sequence, revealing an LXD
sequence in proteins involved in some form of assembly from different viruses.
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rVSV-D125A after 7 passages on 107 cells using an MOI of 0.001 at each passage. As
described below, D125A forms very small plaques and does not cause cell rounding (Fig.
4-2A). The D125E mutation is referred to as a revertant since it restored (data not
shown) the cell rounding activity that was lost in the D125A mutant phenotype when
compared to wild-type (Fig. 4-3A). This phenotype was a significant observation since
BHK-21 cells, which are highly susceptible to VSV cytopathic effects (CPE), did not
round when infected with D125A. A previous study by others showed that infection of
MDCK cells with a rVSV M loop mutant (121-DKQQ-124, rVSV-ΦM) did not show a
wild-type cell rounding but the mutant did in BHK cells (35). To determine if there were
differences in the disruption of the actin- or tubulin-based cytoskeleton within cells
infected with wild-type or the D125A mutant, we examined infected cells by laser
scanning confocal microscopy after staining for M and either tubulin or actin at 8 hours
post infection (hpi). We found that tubulin was not disrupted at this time post infection
(Fig. 4-3B) while actin was reorganized in wild-type infected cells, but not in D125A
infected cells (Fig. 4-3C). The result we observed was interesting since previous studies
using different microscopy and methods had linked the disorganization of microtubules
as the source for virus induced cell rounding (150, 190).
To determine if the growth kinetics of the M loop mutants were similar to rVSVwt we performed single-step growth curves for each virus. All the mutants grew more
slowly and had a titer of one log less than wild-type at 10hpi (Fig. 4-4A). To assess the
relative infectivity of the virions, proteins from 107 PFU of the rVSV-D125A and rVSVwt virions were separated by SDS-PAGE and Coomassie-blue stained (Fig. 4-4B lanes 1
and 2, respectively). The protein compositions from equivalent amounts of infectious
virus were similar indicating the reduced infectivity for D125A found at 10 hpi in the
one-step growth curve analysis was due to less virus being assembled and released from
infected cells. We then compared the morphology of purified virions by transmission
electron microscopy using negative staining. As seen with the relative infectivity
analysis, the morphologies of the D125A loop mutant and rVSV-wt (Wt) were both
bullet-shaped with helically condensed RNPs (Fig. 4-4C). These results further
supported the conclusion that the the reduction in growth kinetics of the loop mutants was
due to an assembly defect.
rVSV M loop mutants show reduced viral protein synthesis at later times
post infection. Previously it was shown that an rVSV M loop, rVSV-ΦM, had a defect
in viral protein synthesis (35) without significant assembly defects. To determine if our
rVSV M loop mutants had similar defects in viral protein translation we infected cells at
an MOI of 10 pulse-labeled the cells with 35S-methionine for 10 minutes at 6 hpi and
analyzed the labeled proteins by SDS-PAGE and phosphorimaging (Fig. 4-5). For each
gel lane 1 shows the protein synthesis of mock infected cells. Quantitation of the
difference in viral protein synthesis between wild-type and the D125(E or A) loop
mutants (Fig. 4-5A lanes 2, 3, and 4, respectively) or the L123(A or S) mutants (Fig. 45B lanes 3 and 4, respectively) is represented in the graphs and shows a larger reduction
in viral protein synthesis for the D125A mutant. The rVSV M loop mutants showed
similar reduced growth kinetics to each other (Fig. 4-4A), but the D125A mutant had a
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Figure 4-3. Cell rounding of rVSV-wt and rVSV-D125A infected cells.
(A) BHK-21 cells were infected with wild-type (Wt) and mutant virions (D125A) at an
MOI of 10 and phase-contrast images were taken at 24 hours post infection (hpi) showing
reduced cell rounding in rVSV-D125A infected cells. (B and C) Cells at 4 hpi were
fixed, permeabilized, and stained for M (Ex. 488nm) and tubulin (B) or actin (C) (Ex.
543nm), showing that reorganization of actin (C, Wt) correlated with cell rounding in
rVSV-wt infected cells.
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Figure 4-4. Characterization of rVSV with M loop mutations.
(A) One-step growth curve of rVSV M mutants and rVSV-wt in BHK-21 cells. The
results show average titers at each time point from the experiment performed in triplicate.
The mutant rVSVs grow to one-log lower titer than Wt. (B) Coomassie-blue stained
SDS-PAGE of 107 PFU for rVSV-D125A (lane 1) and rVSV-wt (lane 2). (C)
Transmission electron micrographs of purified rVSV-D125A (D125A) and rVSV-wt
(Wt) virions. 130,000X, bar represents 20nm.
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Figure 4-5. 35S-methionine metabolic labeling of rVSV infected cells.
(A) SDS-PAGE fluorography of 35S-methionine pulse-labeled BHK-21 cell lysates from
mock infected (lane 1), rVSV-wt (lane 2), rVSV-D125E (lane 3), or rVSV-D125A (lane
4) infected cells at 6 hours post infection (hpi). Quantification of the percent difference
in labeled protein (mutant N/ wt N protein) analyzed by phosphorimaging software is
shown in the graph on the right. (B) SDS-PAGE fluorography of 35S-methionine pulsed
BHK-21 cell lysates from mock infected (lane 1), rVSV-wt (lane 2), rVSV-L123A (lane
3), or rVSV-L125S (lane 4) infected cells at 6 hours post infection (hpi). Quantification
of the difference in protein labeled (mutant N/ wt N protein) analyzed by
phosphorimaging software is shown in the graph on the right.
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more pronounced reduction in viral protein synthesis at 6 hpi (Fig. 4-5). Note all
recovered rVSV M loop mutants were analyzed in the following sections in triplicate but
the rVSV-D125A mutant will be the focus in each of the remaining sections.
To examine the difference in protein synthesis between rVSV-wt and D125A
infected cells in more detail, cells were pulse-labeled with 35S-methionine for 10 minutes
at 2, 4, 6, and 8 hpi and analyzed as described for Figure 4-4. Protein synthesis of viral
and cellular proteins was similar for the two viruses at 2 and 4 hpi, with the characteristic
inhibition of cellular protein synthesis seen from VSV infected cells beginning at 4 hpi.
However, by 6 and 8 hpi there was a dramatic reduction in viral protein synthesis for the
D125A mutant. Lane 1 shows cellular protein synthesis of mock infected cells.
Quantification of viral protein synthesis at 8 hpi from D125A infected cells showed an
82% reduction compared to wild-type levels (Fig. 4-6A (lane 8) and B). To determine if
reduced viral protein synthesis could be observed outside of an rVSV infection, we
transiently expressed the D125A or wild-type M proteins in cells and pulse-labeled the
cells with 35S-methionine at 18 hours post transfection (p.t.) and analyzed cell lysates
immunoprecipitated with an M mAb by SDS-PAGE and phosphorimaging (Fig. 4-6C,
lanes 1 and 2, respectively). We also analyzed protein expression using an in vitro
transcription and translation system and compared the D125A mutant and wild-type by
SDS-PAGE and phosphorimaging (Fig. 4-6D, lanes 1 and 2, respectively). Expression of
D125A without other VSV proteins or products showed no reduced protein synthesis
(Fig. 4-6C and D, lane 1) as observed at 8 hpi (Fig. 4-6A, lane 8) when compared to wildtype. These data suggested that the reduced viral protein synthesis observed is not solely
due to the D125A mutant but requires other viral proteins or products in the context of
infection.
To determine if the reduced viral protein synthesis was due to a reduction in viral
mRNA, we performed quantitative real-time RT-PCR on RNA isolated from infected
cells. Cells were infected with rVSV-wt or rVSV-D125A at an MOI of 10 and RNA
extracts were prepared at increasing times post infection. The amount of genomic RNA
was quantitated by RT-PCR using a VSV genomic standard (Fig. 4-7A), and when the
ratio of P mRNA to genomic RNA was quantitated and we found the amount of P mRNA
per genome was 3 fold higher at 5 hpi and 6 fold higher at 7 hpi in rVSV-D125A infected
cells when compared to rVSV-wt infection (Fig 4-7B). These data showed that a
decrease in viral mRNA synthesis was not responsible for the reduced viral protein
synthesis seen with the D125A mutant. In fact, there was significantly more viral mRNA
in the mutant infected cells than wild-type cells.
To find out if wild-type M could rescue the protein synthesis defect of the D125A
mutant, we used a synchronized fusion assay in a co-infection experiment with rVSV-wt
and rVSV-D125A. Cells were mock infected, infected with rVSV-wt (MOI 1), rVSVD125A (MOI 10), or rVSV-wt (MOI 1) and rVSV-D125A (MOI 10) in the presence of
NH4Cl to synchronize the entry of virions (Chapter 2). This technique was used for the
co-infection experiments because we have observed an increase in cells expressing both
green fluorescent protein and red fluorescent protein from separate viral genomes in coinfected cells when fusion is synchronized as compared to normal (non-synchronized)
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Figure 4-6. Time course of viral protein synthesis by 35S-methionine metabolic
labeling.
(A) SDS-PAGE fluorography of 35S-methionine pulse-labeled BHK-21 cell lysates from
mock infected (lane 1), rVSV-wt (lanes 3, 5, 7, and 9 ), or rVSV-D125A (lanes 2, 4, 6,
and 8) infected cells at increasing time points post infection. (B) Quantification of the
difference in protein labeled (mutant N/ wt N protein) as analyzed by phosphorimaging
software at 8 hours post infection shows an 80% loss in protein synthesis in rVSVD125A infected cells. (C) 35S-methionine pulsed BHK-21 cell lysates from cells
transiently expressing D125A (lane 1) or Mwt (lane 2). (D) 35S-methionine labeled
protein from rabbit reticulolysates of an in vitro transcription and translation of D125A
(lane 1) and Mwt (lane 2).

78

79

Figure 4-7. Quantitative real-time RT-PCR of virus genomes and mRNA during
rVSV infection.
To rule out viral mRNA as the limiting factor in the reduction in protein synthesis at late
time points during infection, RT-PCR was performed on BHK-21 cells infected with
rVSV-wt (Wt) and rVSV-D125A (D125A). (A) Genome equivalents (based on purified
VSV genomic RNA standards) of RNA extracted from cells at increasing time points
post infection, measured by RT-PCR using SYBR green. (B) Levels of P mRNA were
determined using quantitative RT-PCR and the –Wt and D125A mRNA to genome
equivalents ratio was determined. rVSV-D125A infection leads to more mRNA per
genome at 7 hours post infection showing that reduction in viral message did not effect
protein translation.
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infection conditions (Watanabe, Mire, and Whitt, unpublished data). At 9 hpi cells were
pulse-labeled with 35S-methionine and analyzed by SDS-PAGE and phosphorimaging
(Fig. 4-8). We observed that co-infection could partially rescue protein synthesis at this
time point post infection (Fig. 4-8A lane 3 compared to 1) and was up to 60% of rVSVwt infected cells (Fig. 4-8A lane 4 and Fig. 4-8B). These data showed that the D125A M
protein is not a dominant negative mutant for the protein synthesis defect and could be
partially rescued by the wild-type protein.
rVSV M loop mutants show defects in assembly. While we observed reduced
viral protein translation beginning at 6 hpi, we also found that rVSV-D125A titers were
one-log below wild-type (Fig. 4-4A) at 4 hpi when protein synthesis was similar between
the two viruses (Fig. 4-6A, lanes 4 and 5). To determine if virus assembly was affected
by the D125A mutation, we analyzed other assembly functions of M. It was previously
observed that M protein associates with RNPs at the plasma membrane of VSV infected
cells (157). To assess if this association was affected by the D125A mutation, we stained
infected cells for M and N protein at 4 hpi and compared the distribution of the mutant
and wild-type proteins by laser scanning confocal microscopy. The images in figure 49A are representative of infected cells stained with anti-M monoclonal antibody (23H12)
conjugated to FITC and anti-N monoclonal antibody (10G4) conjugated to rhodamine
and examined by 488nm and 543nm laser excitation. We observed similar distributions
for the wild-type (Wt) and mutant (D125A) M proteins, but when we compared the N
distributions in the D125A and wild-type (Wt) infected cells we found the N distribution
during wild-type infection to be more closely associated with the cell periphery near the
plasma membrane (Fig. 4-9A). These data suggested that RNPs were not being
assembled at the plasma membrane as efficiently in rVSV-D125A infected cells when
compared to rVSV-wt infection and we reasoned that this may affect the amount of virus
released.
To determine if release of virions from infected cells was lower in rVSV-D125A
infected cells when compared to rVSV-wt infected cells, we performed viral budding
assays at 4 hpi. Cells were mock infected, infected with rVSV-wt, or rVSV-D125A at an
MOI of 10 and at 3 hpi were pulse-labeled with 35S-methionine for 1 hour. At 4 hpi,
virus was purified from the cell supernatants, cell lysates were collected, and both
released virus and viral proteins in cell extracts were analyzed by SDS-PAGE and
phosphorimaging. When the amount of labeled virus in the supernatant was compared to
the cell lysates from rVSV-D125A it was found that only 1.3% (Fig. 4-9B lanes 5 and 6)
of labeled N protein was released from cells and rVSV-wt had 12% (Fig. 4-9B lanes 3
and 4) labeled N protein released. We then determined whether this effect could be
rescued by the wild-type M protein and we performed synchronized fusion co-infection
experiments as mentioned above but in the context of the viral budding assay just
explained. We observed that infection in the presence of NH4Cl did not affect virus
release for rVSV-wt and rVSV-D125A at 4 hpi since the results were similar to that seen
in Figure 4-9 with wild-type releasing 16% (Fig. 4-9C lanes 1 and 2) of labeled N and the
mutant releasing 0.9% (Fig. 4-9 lanes 3 and 4). However, we determined that coinfection of the virions resulted in partial rescue of virion release as labeled N protein
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Figure 4-8. 35S-methionine metabolic labeling of cells co-infected with rVSV.
(A) Viral protein synthesis in BHK-21 cells was examined in mock infected (lane 1),
infected with rVSV-wt (MOI 1, lane 4), rVSV-D125A (MOI 10, lane 2), or co-infected
(lane 3) by 35S-methionine pulse labeling at 9 hours post infection and cell lysates were
analyzed by fluorography. (B) Quantification of protein synthesis using
phosphorimaging shows a 60% rescue in co-infected cells.
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Figure 4-9. Analysis of assembly defects for rVSV-D125A.
(A) To characterize the distribution of the N and M proteins during assembly, laser
scanning confocal microscopy of rVSV-wt (Wt) or rVSV-D125A infected cells (MOI 10)
at 4 hours post infection was performed. Infected cells were fixed and labeled for the M
(M mAb 23H12 conjugated to FITC) and N (N mAb 10G4 conjugated to rhodamine)
proteins. Magnification using 100X objective for a 1 µm slice in the center of the cell.
(B) Fluorography of cell lysates (odd numbered lanes) and released virus (even numbered
lanes) from a viral budding assay of cells mock infected (lanes 1 and 2), infected with
rVSV-wt (lanes 3 and 4), or rVSV-D125A (lanes 5 and 6) pulse-labeled with 35Smethionine for an hour at 3 hours post infection (hpi). Phosphorimaging was used for the
quantification of labeled N protein in the supernatant (released virus) versus cell lysates.
(C) Co-infection data from viral budding assays as performed and quantified in (B). (D)
RNP exchange assay. rVSV-wt (Wt RNP) or rVSV-D125A (D125A RNP) RNPs at 10,
50, or 100 µg were incubated with 35S-methionine labeled Mwt or D125A produced by in
vitro translation and the mixtures were ultracentrifuged over sucrose cushion to separate
RNPs with associated M proteins incorporated input M (P; pellet) and un-incorporated M
(S; supernatant).
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released was near 8% (Fig. 4-9C lanes 5 and 6). These results suggested the D125A
mutant M was not dominant negative for reduction virion assembly and release.
To determine if the decrease in virus release was due to inefficient condensation
of RNPs by the D125A loop mutation, we performed an RNP exchange assay. Ten, 50,
or 100 µg of purified rVSV-wt or rVSV-D125A was detergent solubilized in the presence
of 35S-methionine labeled Mwt or D125A that had been synthesized in an in vitro
translation system to allow exchange of the labeled M proteins with the RNPs of the
virions. The RNPs were then separated from the supernatant by ultracentrifugation and
the pellet and supernatant analyzed by SDS-PAGE and radiofluorography. We observed
that the Wt RNPs did not incorporate any input 35S-methionine labeled M protein even
with 100 µg of virus where more RNPs are available to exchange with input M (Fig. 49D, Wt RNP, P), while the D125A RNPs exchanged with each of the input labeled M
proteins (Fig. 4-9D, D125A RNP, P). These data suggested that the D125A M protein
was less tightly associated with the RNP derived from D125A virus and therefore
resulted in exchange with input M.
Reduction in viral protein synthesis is not due to classical host responses,
apoptosis, or autophagy. To determine if the classical host responses to RNA viruses
that can cause inhibition of viral and host protein synthesis were responsible for the
reduced protein synthesis seen in rVSV-D125A infected cells, we examined the end
products of RNase L and PKR activation. Cells were mock infected, infected with rVSVwt, or rVSV-D125A at an MOI of 10 and at increasing times post infection RNA was
extracted for formaldehyde agarose electrophoresis (Fig. 4-9A) or cells lysates were
separated by SDS-PAGE and analyzed by immunoblotting (Fig. 4-9B). To determine if
RNase L was activated resulting in more degraded ribosomal RNA (rRNA) in the rVSVD125A infected cells, we examined extracted RNA on a RNA denaturing gel and
observed that there were no degradation products from the 28S and 18S rRNA (Fig. 410A) where one would expect to see these products after RNase L activation. We then
examined the cell lysates by immunoblotting for phosphorylated eIF2α to determine if
PKR activation was higher in cells infected with rVSV-D125A when compared to rVSVwt infection. We observed no increase in phosphorylation of eIF2α in rVSV-wt and
rVSV-D125A infected cells (Fig. 4-10B lanes 1-3, respectively). Taken together these
data showed that neither classical response was involved in the decreased protein
synthesis observed in D125A infected cells.
We used HeLa cells to analyze interferon, apoptosis, and autophagy responses to
rVSV-D125A and rVSV-wt infections because the reagents required the use of human
cells or only recognized human proteins. To determine if the reduced titers and protein
synthesis phenotype of the D125A mutant were found in human cells we infected HeLa
cells at an MOI of 10 and assessed total protein synthesis and virus production as
described for the BHK-21 cell experiments. As seen in BHKs, protein synthesis was
decreased for the rVSV-D125A (Fig. 4-11A lanes 6 and 8) when compared to rVSVwt
(Fig. 4-11A lanes 5 and 7) but the reduction was somewhat delayed in HeLa and occurred
at 6 hpi versus 4 hpi. The rVSV-D125A viruses also grew to lower titers in HeLa cells
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Figure 4-10. Analysis of PKR and RNaseL activation in rVSV-D125A infected cells.
BHK-21 cells were mock infected (lane 1), infected at MOI 10 with rVSV-wt (lane 2) or
rVSV-D125A (lane 3) and at 7 hours post infection cell extracts were collected and RNA
was analyzed by denaturing gel electrophoresis (A) or by immunoblot analysis (B). (A)
2% formaldehyde-agarose gel of 2μg total input RNA to assess RNaseL activation. (B)
Immunoblots using monoclonal antibodies to Tubulin, eIF2α, and phosphorylated eIF2α
was used to assess PKR activation.
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Figure 4-11. Analysis of reduced protein synthesis and host cell response in HeLa
cells.
(A) HeLa cells were infected with rVSV-wt (lanes 1, 3, 5, and 7) or rVSV-D125A (lanes
2, 4, 6, and 8) at an MOI of 10 and pulse-labeled with 35S-methionine at increasing times
post infection. (B) rVSV-wt (Wt) and rVSV-D125A (D125A) titers at 8 hours post
infection from single-cycle infection in HeLa cells. (C) HeLa cells transfected with a
plasmid that expressed luciferase under the control of the IFNβ promoter were treated
with 125U of human IFNβ, or infected with rVSV-wt (Wt) or rVSV-D125A (D125A)
and cell lysates were assessed for luciferase activity at 6 hours post infection. (D)
Immunoblots of HeLa cell lysates from mock infected/untreated (lane 1) or rapamycin
treated (lane 2) cells, and cell lysates from rVSV-wt (lanes 3, 5, and 7) or rVSV-D125A
(lanes 4, 6, and 8) infected cells at increasing times post infection detecting
phosphorylated eIF2α, full-length and cleaved caspase 3, phosphorylated eIF4G, LC3B,
VSV M, and tubulin using monoclonal antibodies.
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(also in NIH 3T3 and Vero cells; data not shown) when compared to rVSV-wt (Fig. 411B). These data showed the effects on protein synthesis and assembly were not
restricted to BHK cells but also occurred in HeLa cells.
To determine if rVSV-D125A infection could lead to a more robust interferon
response, we transfected cells with a luciferase reporter plasmid under the control of the
interferon (IFN)β promoter and at 5 hours post transfection the cells were treated with
human (hu)IFNβ, or they were infected with rVSV-D125A or rVSV-wt. At 6 hpi we
observed no difference between the luciferase activity from the IFNβ promoter in cells
infected with either virus (Fig. 4-11C). These data showed that in these cells increased
IFN inducible gene expression is not responsible for the reduction in rVSV-D125A
infected cells.
To determine if eIF2α phosphorylation, apoptosis, or autophagy could cause
reduced protein synthesis in rVSV-D125A infected HeLa cells when compared to rVSVwt infection, cells were mock infected or treated with rapamycin to induce autophagy as a
control, and were infected (MOI 10). Cell lysates were collected at 6, 10, and 12 hpi and
analyzed by immunoblot. Phosphorylation of eIF2α was enhanced in rVSV-D125A
infected cells at 12 hpi but not at 6 hpi (Fig.4-11D lanes 8 and 6, respectively) where we
observed reduced viral protein synthesis suggesting PKR activation is not involved in this
effect seen at earlier times post infection. Apoptosis was ruled out as a possible
mechanism for this effect as there was no difference in the cleavage of caspase 3 between
rVSV-D125A and rVSV-wt infected cells (Fig. 4-11D, lanes 3-8). To examine the role
of autophagy in reduced viral protein synthesis we examined proteins affected by this
process and compared them between the two types of virus infected cells. Rapamycin
treatment resulted in the complete conversion of LC3 protein to the LC3B form and the
dephosphorylation of eIF4G, which is an important protein in the initiation of protein
synthesis (Fig. 4-11D lane 2). However, we observed no difference between these
autophagy markers within cells infected with rVSV-D125A or rVSV-wt. Overall, these
data showed that PKR activation, induction of apoptosis, and autophagy were not
involved in the reduction in viral protein synthesis seen in rVSV-D125A infected cells.
rVSV infection does not reduce cap-independent protein synthesis. To
determine if protein synthesis from a Type 2 internal ribosome entry site (IRES) could be
affected in rVSV-D125A infected cells, we transfected BSR cells constitutively
expressing T7 polymerase with a plasmid that has a T7 promoter used to produce an
mRNA with an encephalomyocarditis virus (EMCV) IRES for cap-independent protein
synthesis of a luciferase reporter gene. At 18 hours p.t., cells were mock infected, treated
with cycloheximide, or infected with rVSV-wt or rVSV-D125A at an MOI of 10. Cell
lysates were then analyzed for luciferase activity in a luminometer at increasing times
post infection. Luciferase activity of cell lysates from mock infected and cycloheximide
treated BSRs at 6 hpi (of treatment) showed the basal level and background luciferase
activity, respectively (Fig. 4-12). It is interesting to note that at 6 hpi both rVSV-wt and
rVSV-D125A infected cell lysates have higher luciferase activity than the mock infected
cells. This effect may be due to restriction of host mRNA export from the nucleus which
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Figure 4-12. EMCV/IRES expression of luciferase in rVSV infected BSR cells.
BSR cells constitutively expressing T7 were transfected with a plasmid that expresses
IRES-luciferase from a T7 promoter. Eighteen hours post transfection; BSR cells were
mock treated/infected or treated with cycloheximide, or infected rVSV-wt (Wt) or rVSVD125A (D125A). Luciferase activity was measured at 6 hours post treatment for
cycloheximide treated cells and at increasing times post infection for infected cells.
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would reduce the competition for ribosomes by the cytosolic luciferase mRNA since in
another experiment we found that both viruses were capable of limiting luciferase
expression from a chicken actin promoter, which occurs in the nucleus by RNA
polymerase II (data not shown). The results of this experiment also showed that the
luciferase activity of cell lysates from both viruses did not significantly differ over the
course of infection suggesting that the reduced protein synthesis seen at increasing time
points post infection in rVSV-D125A infected cells only affected synthesis of proteins
produced by a cap-dependent mechanism.

Discussion
The crystallization of the VSV M protein was made possible by proteolytic
cleavage of an exposed loop that prevented the protein’s self-association (10, 65-68).
The self-association is affected by high ionic concentrations (67) and these salt conditions
have also been shown to cause the decondensation of skeletons in an M-dependent
manner (154). Altogether, these observations suggested that the exposed loop may be
involved in the assembly of virions in regards to condensation of RNPs into skeletons.
Others made mutations at amino acids 121 to 124 within this loop and a minor assembly
defect was observed but there was an unexpected reduction in viral protein synthesis for
this mutant rVSV (35). Here we report on a mutational analysis of different amino acids
found within this loop with a focus on the conserved aspartate at residue 125.
There were no discernable differences in cellular distribution and budding activity
for the M loop mutants when compared to Mwt. However, rVSV encoding only four of
the eight mutations could be recovered after multiple attempts (n = 6 per virus). These
data suggested that the amino acids and size of the loop were important for recovery and
therefore for assembly of virus. Indeed, we saw reduced growth kinetics (Fig. 4-4A) and
virus budding (Fig. 4-9B) for the four rVSV M loop mutants that were recovered when
compared to wild-type rVSV. We also observed what appeared to be a build-up of N
protein (RNPs) within rVSV-D125A infected cells when compared to rVSV-wt (Fig. 49A) and we reasoned that this may be due to inefficient condensation of RNPs at the
plasma membrane much like the build-up of uncondensed RNPs that occurs in the M
protein temperature-sensitive mutant (tsG33) infected cells at non-permissive temperature
(160). There were also additional observations that suggested RNPs may be inefficiently
condensed. One was the high viral mRNA to genome ratio found in the rVSV-D125A
infected cells when compared to rVSV-wt infection as M condensation of the RNP is
thought to inhibit transcription (163). The other was that rVSV-D125A RNPs could
exchange with more Mwt or the M D125A loop mutant proteins when compared to
rVSV-wt RNPs (Fig. 4-9D) where exchange of M protein is thought to be indicative of
the condensed nature of RNPs (57). These data correlated with the proteolytic cleavage
data that suggested the exposed loop may be important in virion assembly (65, 66).
These were not the only observations that we made in regards to the M loop mutations as
we also noticed a reduction in viral protein synthesis (Fig. 4-5 and 4-6A).
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The observation that the rVSV-D125A mutant had a reduction in protein
synthesis was also observed previously with different M loop mutations (35). The
assembly defects and higher viral mRNA to genome ratio phenotypes of the rVSVD125A mutant led us to reason that there may be more viral products within infected
cells to provide a more robust antiviral response to the D125A mutant when compared to
wild-type. To test the classical antiviral responses of cells to RNA virus infection that
result in reduced protein synthesis, we compared PKR and RNaseL activation (196) in
cells infected with rVSV-D125A and rVSV-wt for differences in phosphorylation of
eIF2α and degradation of rRNA and found these were not responsible for the reduction
(Fig. 4-10). The expression IFN which leads to subsequent signaling events that produce
and antiviral response that controls VSV replication (197), was also we examined by
luciferase expression from an IFNβ promoter and it was found that there was no
difference in the induction of IFN between the rVSV-wt and D125A mutant viruses,
suggesting this was not responsible for the reduced viral protein synthesis (Fig. 4-11C).
The experiment examining activity from the IFNβ promoter was performed in HeLa
cells, but another cell line with a more robust IFN response like plasmacytoid dentritic
cells (pDCs) may be a more appropriate cell to infect and to evaluate potential differences
before completely disregarding the role of this pathway.
VSV can cause apoptosis in infected cells (106) but enhanced apoptosis did not
appear to be involved in this reduction as there was no difference in cleavage of proCaspase 3 to caspase 3 when loop mutant and wild-type infected cells were compared
(Fig. 4-11D). Recently, it was reported that the IFN response to VSV infection in pDCs
was toll-like receptor 7 (TLR7) and autophagy dependent (118). This revealed a new
model for how cells can autophagocytose viral ssRNA and traffic the RNA to TLR7. We
therefore measured this response by examining the conversion of LC3 to LC3B in
infected cells and found no difference between the virus infected cells. Altogether, these
results suggest that the reduced viral protein synthesis may not be a host cell response,
our analysis was not exhaustive as other responses like those through the cytosolic
pattern recognition receptors such as RIG-I could be involved (187).
Recently, the VSV field has gained insight on how control of the translation of
host and viral proteins is accomplished in VSV infected cells. It was shown that
dephosphorylation of the eIF4E complex was responsible for the reduction of host protein
synthesis (34) and phosphorylation of eIF2α controls viral protein synthesis at later times
post infection (33). A new model has been proposed for translation during infection
where dephosphorylation of eIF4E results in inhibition of host protein synthesis and the
host mRNA is then shuttled to inactive mRNPs which in turn allows for newly made viral
mRNA to be translated (208) and this process may be enhanced between 4 to 8 hpi by M
(13, 35, 208). This is particularly interesting since we observed a reduction in viral
protein synthesis from 4 to 8 hpi (Fig. 4-6A), which we assumed was the result of a host
response since protein synthesis was similar at early times post infection. However this
may reflect the inability of the D125A loop mutant to positively regulate viral protein
synthesis.
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Eukaryotic protein translation initiation is a complex process that requires many
co-factors but the cap-independent translation of mRNA from picornaviruses such as
encephalomyocarditis virus (EMCV) requires a smaller number of initiation factors when
compared to the number required for cap-dependent translation initiation (167). EMCV
mRNA contains a 5’ untranslated region (UTR) that has an internal ribosome entry site
(IRES) (83, 89) and translation from the IRES in vitro only requires ATP, eIF2, eIF3,
eIF4A or eIF4E, and the central portion of eIF4G (167). Although it is still possible that
the reduction in viral protein synthesis was due to a host response that was enhanced due
to inefficient virus assembly, our results suggested that the effect was more likely due to
the inability of the loop mutant proteins to up-regulate VSV translation. To determine if
any of the factors required for translation from the EMCV IRES were affected during
rVSV-D125A infection, we examined translation of luciferase expressed from an EMCV
IRES and found it was not significantly affected by rVSV-D125A infection.
Interestingly, there was an increase in luciferase at 6 hpi in infected cells when compared
to mock infected cells (Fig. 4-12) where newly made viral mRNA should be
preferentially translated (208). These data implicate that eIF4E may be the factor
involved in the protein synthesis effect observed during rVSV M loop mutant infections
(35) since it is the only major initiation factor that is not required for EMCV IRES
protein translation initiation but is required for cap-dependent β-globin mRNA translation
(167). Importantly, it has been shown that VSV infection affects host protein synthesis
by dephosphorylation of eIF4E (34) and a model was proposed that the short UTR of
VSV mRNA did not require phosphorylated eIF4E for translation initiation (33) and
therefore viral protein synthesis was not affected. The short UTR model was tested by
expression of protein from rVSV genomes that had long UTRs on the mRNA and it was
observed that the mRNA with long UTRs were translated as efficiently as mRNA with
shorter UTRs (209). This led to the model suggesting that it was the timing of the mRNA
synthesis that allowed for preferential translation (208). The data presented here
together with that published by others (13, 33-35, 208, 209) suggests that M protein may
regulate viral translation by playing a supporting role for the loss of phosphorylated
eIF4E and that the exposed loop of M (amino acids 121 to 125) is involved in this
regulation to allow cap-dependent translation of newly synthesized mRNA. However,
not only may this loop be involved in protein translation enhancement, but also we show
that it is required for efficient assembly. Whether these two phenotypes can be separated
genetically will require additional investigation.
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Chapter 5: General Discussion
VSV Entry and Uncoating
Entry and uncoating of enveloped viruses has been examined for the past three
decades but new technologies over the past 10 years have made it possible to gain further
insight into these processes [reviewed in (114, 136)]. Virions entering a cell have highly
condensed genomes protected by proteins. Before these particles can replicate in a host
cell, after fusion and entry, uncoating must occur and this is described as the dissociation
of the proteins condensing the genome. Once the genome has uncoated, replication of the
virus can begin and this process is the opposite of what occurs to package the virus for
release. Here lies the question; how can a virus accomplish these two distinct events
using the same protein? It has been shown how influenza virus, another enveloped
negative-strand RNA virus, can accomplish this through virus-host interactions. Studies
on Sindbis virus and Semliki Forest virus have also suggested virus-host interactions in
uncoating. Based on the available details for VSV entry and influenza, Sindbis, and
Semliki Forest virus entry and uncoating, I am proposing a model for VSV entry and
uncoating with a focus on the events that occur right before fusion and after release into
the cytosol.
Upon entry, the VSV virion must be disassembled. The structure of the virion
is composed of a helical nucleocapsid, containing L-P-N-RNA-M, surrounded by a
membrane derived from an infected host cell membrane with transmembrane, trimeric G
proteins protruding from the surface. The RNA genome is encapsidated by N protein and
RNA-dependent RNA polymerase, consisting of the L and P proteins, is associated with
this ribonucleoprotein complex (199). The L-P-N-RNA complex makes up the
ribonucleoprotein particle (RNP) which is coiled into a tightly packed helix and the M
protein condenses the RNP into this tightly packed helix, called the skeleton (153, 154).
Also a population of membrane bound M anchors the skeletons to the viral membrane
(31, 151). Viral uncoating, in the case of VSV, is regarded as the dissociation of M from
RNPs and is an essential step in entry (130). Without the release of M protein
transcription of viral mRNAs (productive infection) cannot proceed since it has been
shown that M protein inhibits transcription (32, 44, 212).
VSV entry. When VSV enters the host cell through the clathrin-mediated
endocytic pathway (139), it uses the decreasing pH of endocytic organelles as a trigger
for fusion in order to penetrate the cell as is the case for influenza virus (207). In our
model, VSV virus attaches to the surface of a cell and is endocytosed by coated vesicles
(Fig. 5-1A) and transported through the endosomal pathway to early endosomes (Fig. 51B). In early endosomes (189), pH-dependent fusion of the endosomal and viral
membrane occurs (Fig. 5-1C) and the G protein is directly responsible for these entry
steps (18, 82, 134, 161, 198, 211). Our model presents early endosomes as the location
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Figure 5-1. VSV entry model.
(A) Attachment to the cell surface by VSV. (B) Subsequent clathrin-mediated
endocytosis of a VSV particle in a coated pit (orange stars depict clathrin scaffolding)
that leads to Rab5 dependent trafficking to the early endosomes where a pH-dependent
conformational change occurs for G (C) resulting in acidification of the virion interior
(D). Acidification of interior of the virion has an effect on the M protein (E, bluebordered stars) and results in an enhanced dissociation of M after fusion (F). The bulk of
M remains associated with endosomes and is trafficked to the recycling endosomes where
M is thought to be located at the point of fusion (G). A smaller fraction of M is released
into the cytosol and reaches the NPCs in a microtubule and actin independent manner
(H). Events observed in steps G and H correlate with replication of RNPs that have
uncoated.
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of fusion and release of RNPs based on Rab5 dominant negative (189) and nocodazole
(42) studies that indicate fusion does not require transport to late endosomes as another
group has recently suggested (117).
Acidification of the VSV interior and its effect on M. Our model proposes that
the interior of VSV becomes acidified over the course of entry in a G-dependent manner
(Fig. 5-1D). This is a different mechanism than the one used for influenza as discussed in
Chapter 3 (Discussion section) but results in a similar enhancement of the uncoating of
the M protein. Since the M associated with purified RNPs is not sensitive to acidic
conditions [(130), and our lab’s unpublished data] our model has the pH affecting the
interaction between the membrane bound and RNP bound M (Fig. 5-1E, blue-bordered
stars) which allows the release of RNPs from endosomes after fusion. The release of
RNPs could be a general unwinding of the RNP from one end or release of the condensed
RNP as depicted in figure (5-1F).
Completion of uncoating and the subsequent distribution of M. In our model,
after the release of the skeleton from the membrane bound M, the bulk of the M protein
remains associated with endosomes that traffic to the recycling endosomes (Fig. 5-1G).
Although binding to one side of the endosome by the G of unfused virions or the reassociation of released M protein to endosomes cannot be completely ruled out, the
separation of M and the RNPs at these locations and the fact that only misfolded
temperature-sensitive M mutants have been seen to associate with vesicles in cells (132)
suggests that these are points of fusion. The RNP associated M then releases from the
RNPs into the cytosol as previously proposed (130) and reaches the nucleus and binds the
NPCs by diffusion (Fig. 5-1H). Diffusion of M to the NPCs is proposed here since the
protein could reach the nucleus and separate from RNPs without the need for actin or
microtubules; however an undiscovered mode of trafficking perhaps using RaeI or
vesicular transport that is not dependent on these two cytoskeletal elements cannot be
ruled out. Brefeldin A inhibition of retrograde transport could rule out that transport
process in the trafficking to NPCs (27). siRNA knock down or use of dominant negatives
of the known Rab GTPases involved in vesicular trafficking may also be ways to rule out
known vesicular pathways that are commandeered by bacterial pathogens to survive
within host cells (23). The binding of M to NPCs has been proposed previously as the
first cytopathic effect of VSV (60) and one could reason that directly after release of M
the association with the NPCs would give the virus the ability to prevent antiviral
responses requiring gene expression before the virus has started replication.

VSV Assembly
The assembly of VSV virions, which is the reverse process of uncoating, has been
studied extensively and a model has been proposed by our lab (90). Proteolytic cleavage
of an exposed loop prevented M self-association (10, 65-68) and this self-association has
been implicated in condensation of skeletons (154). These observations suggested that
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the exposed loop may be involved in the assembly of virions in regards to condensation
of RNPs into skeletons. Others made mutations at amino acids 121 to 124 within this
loop and a minor assembly defect was observed, but there was an unexpected reduction
in viral protein synthesis for this mutant rVSV (35).
The current model from Jayakar, et al. (90), outlines 5 steps in VSV assembly.
The first step is encapsidation of anti- or genomic RNA by the N protein in the cytoplasm
while some M may bind to the nucleocapsid but not enough for condensation. The
second step occurs during N encapsidation of genomic RNA, where G protein is
trafficked to microdomains at the cell surface forming favorable sites for condensation of
RNPs by M protein. The third step consists of M association at the plasma membrane
(during steps 1 and 2) and condensation of RNPs into skeletons with cytosolic M protein
at G-enriched microdomains. At the fourth step, the condensation of skeletons resulting
in eversion of the the plasma membrane resulting in an enveloped skeleton by recruitment
of membrane and cytosolic M proteins, resulting in bullet shaped evaginations of the
membrane. In the final step of the model, the host cell multivesicular body (MVB)
fission machinery associates with the PY motif of M through a ubiquitin ligase and this
interaction, whether direct or indirect, results in fission and release of mature progeny
virions.
Based on the assembly model from our lab, I propose a model for the involvement
of the exposed loop in efficient binding to and condensation of RNPs by M during VSV
assembly. Initiator M (Mi) has been proposed and is yet to be identified however
nucleation sites are needed for full scale M self-association to occur (67) and one can
imagine a scenario where Mi can bind to RNPs before they reach the plasma membrane
to prime the RNPs for condensation by M protein undergoing self-association. Also M
inhibits viral transcription within infected cells and this does not necessarily occur at the
plasma membrane so Mi could be responsible for the phenomenon. The cleavage of the
exposed loop of M by thermolysin resulted in Mth which could not form, nor be recruited
into nucleation sites (65). I propose a model where the conserved aspartate at residue 125
is involved in the process of initial binding of Mi to RNPs (Fig. 5-2, between I. and II.)
and the efficient condensation of RNPs at the plasma membrane (Fig. 5-2, V.) as
evidenced by the build up of N protein, hyper-transcription of viral mRNA in rVSVD125A infected cells and the increased ability of the RNPs from virions to exchange with
introduced M. This model also includes the most recent model for how budding sites are
formed, where RNPs and G initially associate at microdomains before incorporation of M
at these sites (195) (Fig. 5-2, III.). The importance of the hypervariable hinge region of P
in assembly (43) may be the important factor in the initiation of association of RNPs at
budding sites or for condensation by M (Fig. 5-2, III. and IV., respectively). Also
observations from Chapter 2 revealed M chimeras with large C-terminal fusions affect
budding activity suggesting that the PY motif interactions with Nedd4 or an MVB
complex are sterically hindered by these C-terminal extensions thereby reducing the
budding activity of M protein (Fig. 5-2, VI.).
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Figure 5-2. VSV assembly model.
(I.) Genomic RNA is encapsidated by N protein while G protein trimers form
microdomains at the virus budding site (II.). Initiator (Mi, orange circles) has been
proposed previously (90) and as described in the General Discussion the LXD sequence
of the M protein may be important for forming nucleation sites formed by the Mi. After
the proposed binding of Mi to the RNP this complex is then trafficked to the plasma
membrane where it associates in microdomains with G (III.) and then M (membrane
bound green circles) is incorporated to these microdomains (IV.) as recently shown (195).
The role for P, in particular residues 191 to 200, in assembly has been reported recently
and it may be involved in steps III. or IV. (V.) After the budding site has been formed
the membrane bound M, Mi, and cytosolic M (black-rimmed green circles) participate in
the helical condensation of the RNP and this process is proposed to be less efficient in M
proteins with mutations in the LXD sequence. (VI.) Progeny virions then bud from the
host cell in an M protein PY motif dependent manner where it has also been shown that
large C-terminal extensions affect budding.
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VSV Translation
Recently, a new model has been proposed for translation of viral proteins during
infection where dephosphorylation of eIF4E results in inhibition of host protein synthesis
and the host mRNA is then shuttled to inactive mRNPs which in turn allows for newly
made viral mRNA to be translated (208). The translation of newly made viral mRNA
which occurs between 4 to 8 hpi, may be enhanced by M (13, 35, 208). In Chapter 4 we
observed a reduction in viral protein synthesis between 4 and 8 hpi and I propose here
that the M D125A loop mutation results in the inability of the mutant to support viral
protein synthesis.
Based on the new virus translation regulation model mentioned above, our model
proposes that M protein supports viral translation by playing a supporting role, after the
dephosphorylation eIF4E, for cap-dependent translation of newly synthesized viral
transcripts. Based on the D125A phenotype, the exposed loop of M (amino acids 121 to
125) is involved in this regulation (Fig. 5-3). It has to be said that the protein translation
and assembly effects have not been separated and for now we designate this loop as
important for both of these events. The alignment of proteins retreived from a PubMed
blast search of the exposed loop of M revealed a potential LXD motif that could be
important in one or both of the phenotypes observed for the loop mutants.

Future Directions
The models presented here are a combination of the current views from the
literature and my work. However, these models require further investigation to clarify
the “black boxes” that still exist. In the entry model (Fig. 5-1) for instance, the exact
location of M that associates with the recycling endosomes after VSV entry can be
visualized using photoconversion of diaminobenzidine (DAB) by Lumio-RedTM from
rVSV-M-Lumio-Red virus for high resolution TEM. In the assembly model (Fig. 5-2),
the condensed nature of the LXD mutant RNPs can be further examined by light
scattering analysis when compared to wild-type. The spacing between the helical turns of
the RNPs in TEM visualization could also be measured and analyzed for statistical
significance to determine if there is any difference between the LXD mutant and wildtype RNPs. In the translation model (Fig. 5-3), the exact mechanism for how M supports
viral protein synthesis from viral mRNA still needs to be examined. In the model
dephosphorylated eIF4E is present in the initiation complex and M is depicted in support
but it may be that M replaces eIF4E in this complex altogether. Further investigation into
the idea that M may replace eIF4E is intriguing since the proteins are similar in size, have
a pleiomorphic N-terminus, and similar crystal structure (20, 66). This is particularly
interesting since there is an unanswered question about why M is phosphorylated (98, 99)
where phosphorylation may be required for the support of viral protein synthesis after 4
hpi. Analysis of viral protein synthesis after 4 hpi using phosphorylation site mutants
could certainly a way to examine this hypothesis. While there are “black boxes” that still
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Figure 5-3. VSV translational support model for M.
(Left-hand column) After 4 hours post infection (hpi) cellular protein synthesis is
inhibited by dephosphorylation of eIF4E and the sequestration of host mRNA to mRNPs
(33, 208). However, this model proposes that M can support viral protein synthesis after
the dephosphorylation of eIF4E and the loop (yellow loop on red M) is important for this
especially the LXD sequence of M, however the manner in which this occurs is open for
speculation.
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exist in the models for VSV replication, additions to these models that help clarify the
“black boxes” are important to the contribution of VSV as the prototype Rhabdovirus and
may contribute to insights into replication of viruses within the order Mononegavirales.
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